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1 Abbreviations 
Aa  Amino acids 
ABTS  2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) 
ADP  Adenosine diphosphate 
Akt/ PKB  Protein kinase B 
APP  Amyloid precursor protein 
ARF6  ADP ribosylation factor 6 
BAR  Bin/amphiphysin/rvs 
BM  Basement membrane 
BSA  Bovine serum albumin 
Ca  Calcium 
CCD  Charge-coupled device 
Cdc42  Cell division cycle 42 
cDNA  Complementary DNA 
CNS  Central nervous system 
Dab  Disabled 
Dab2  Disabled homolog 2 
DAPI  4',6-diamidino-2-phenylindole 
DNA  Deoxyribonucleic acid 
E7.5  Day 7.5 of embryonic development 
EB  Embryoid body 
EBS  Epidermolysis bullosa syndrome 
ECM  Extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid 
EEA1  Early endosome antigen 1 
eGFP  Enhanced green fluorescent protein 
EGFR  Epidermal growth factor receptor 
EGTA  Ethylene glycol tetraacetic acid 
ELISA  Enzyme-linked immunosorbent assay 
ERK  Extracellular-signal-regulated kinase 
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ES  Embryonic stem 
ESCRT  Endosomal sorting complex required for transport 
FA  Focal adhesion 
FACS  Fluorescence-activated cell sorting 
F-actin  Filamentous actin 
FAK  Focal adhesion kinase 
FBS  Fetal bovine serum 
FC  Focal complex 
FERM  Band4.1/ezrin/radixin/moesin 
FGFR  Fibroblast growth factor receptor 
FITC  Fluorescein isothiocyanate 
FN  Fibronectin 
GAP  GTPase activating protein 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GEF  Guanine nucleotide exchange factor 
GID  Guanine nucleotide dissociation inhibitor 
GST  Glutathione S-transferase 
GTPase  Guanosine triphosphatase 
HAX1  HCLS1-associated protein X-1 
HCLS1  Hematopoietic lineage cell-specific protein 
HE  Haematoxilin and eosin 
HEK  Human embryonic kidney 
HRP  Horseradish peroxidase 
IAA  Iodoacetamide 
ICAM-1  Intracellular adhesion molecule-1 
IF  Immunofluorescence 
Ig  Immunoglobulin 
ILV  Intraluminal vesicle 
IP  Immunoprecipitation 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
ITR  Inverted terminal repeat 
Krit1  Krev-interaction trapped 1 
Abbreviations 
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LAD  Leukocyte-adhesion deficiency 
Lamp1  Lysosomal-associated membrane protein 1 
LAP  Latency associated peptide 
LDLR  Low density lipoprotein receptor 
LDV  Leucine-aspartic acid-valine 
LFA1  Lymphocyte function-associated antigen 1, integrin αLβ2 
LIF  Leukemia inhibitory factor 
LN  Laminin 
LRP1  Low density lipoprotein receptor related protein 1 
mAb  Monoclonal antibody 
MAdCAM-1 Mucosal addressin cell adhesion molecule-1 
mCherry  Monomeric Cherry 
MEF  Mouse embryonic fibroblasts 
Mesna  Sodium 2-mercaptoethanesulfonate 
Mg  Magnesium 
MIDAS  Metal-ion dependent adhesion sites 
Mn  Manganese 
mRFP  Monomeric red fluorescent protein 
mRNA  Messenger ribonucleic acid 
MS  Multiple sclerosis 
MVB  Multivesicular body 
NFκB  Nuclear factor κ-light-chain-enhancer of activated B cells 
NHS-LC-biotin Succinimidyl-6-(biotinamido)hexanoate 
NHS-SS-biotin Succinimidyl-2-(biotinamido)-ethyl-1,3'-dithiopropionate 
NLS  Nuclear localization signal 
NRP1  Neuropilin 1 
PBS  Phosphate-buffered saline 
PBSST  0.1% Triton-X, 5% BSA in PBS 
PBS-T  PBS + Tween 20 
PCR  Polymerase chain reaction 
PE  Phycoerythrin 
PFA  Paraformaldehyde 
Abbreviations 
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PH  Pleckstrin homology 
PI3  Phosphatidylinositol 3 
PLCγ1  Phospholipase C γ1 
PML  Progressive multifocal leukoencephalopathy 
PNRC  Perinuclear recycling compartment 
PNS  Peripheral nervous system 
PTB  Phosphotyrosin-binding 
PtdInsP, PIP Phosphatidylinositol phosphate 
PX  Phox homology 
qRT  Quantitative real-time 
Rab  Ras-associated binding 
Rac1  Ras-related C3 botulinum toxin substrate 1 
Ras  Rat sarcoma 
RCP  Rab-coupling protein 
RGD  Arginine-glycine-aspartic acid 
RhoA  Ras homolog gene family, member A 
RIPA  Radioimmunoprecipitation assay 
RNA  Ribonucleic acid 
Rpm  Revolutions per minute 
RT  Room temperature 
RTK  Receptor tyrosin kinase 
SD  Standard deviation 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM  Standard error of the mean 
SH3  Src Homology 3 
shRNA  Short hairpin RNA 
SILAC  Stable isotope labeling by amino acids in cell culture 
siRNA  Small interfering RNA 
SLIC  Sequence- and ligation-independent cloning 
SNX  Sorting nexin 
SV40  Simian virus 40 
TBS  Tris-buffered saline 
Abbreviations 
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TCR  T-cell receptor 
Tfr  Transferrin receptor 
TGFβ  Transforming growth factor β 
TGN  Trans-Golgi network 
THD  Talin head domain 
TSG101  Tumor susceptibility gene 101 
UB  Ureteric bud 
VCAM-1  Vascular cell adhesion molecule-1 
VEGF  Vascular endothelial growth factor 
VN  Vitronectin 
WB  Western blotting 
Wcl  Whole-cell lysate 
Wt  Wild type 
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2 Introduction 
2.1 Integrin adhesion receptors 
Integrins are major type I transmembrane receptors mediating adhesion to the extracellular 
matrix (ECM) as well as other cells. One of 18 α and one of 8 β subunits are non-covalently 
associated and form a plethora of at least 24 different integrin heterodimers (Hynes 2002), 
each of them specific for certain ECM components such as fibronectin (FN), laminin (LN) or 
collagen as well as soluble ligands or cell surface components (Humphries et al. 2006) (Figure 
1). 
 
Figure 1: The integrin receptor family 
Depicted are the 18 α and 8 β subunits and their 24 potential heterodimer associations divided 
into four subclasses of integrin receptors according to major ligands or leukocyte-specific 
expression (adapted from Hynes 2002 (Hynes 2002)). 
Introduction 
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Integrin receptors can be classified into four distinct groups according to specific ligands or 
cell-type specific expression patterns. The first three groups are characterized by their main 
ligand including collagen, LN and RGD (arginine-glycine-aspartic acid)-motif specific 
integrins, which bind ECM components such as FN, vitronectin (VN), thrombospondin, 
osteopontin and tenascin. However, the collagen receptors α1β1, α2β1, α10β1 and α11β1 have 
also been described to bind LN (Humphries et al. 2006). The fourth group is defined by its 
cell-type specific expression on leukocytes and recognizes the tripeptide motif LDV (leucine-
aspartic acid-valine) or similar motifs, which are typically present in endothelial ligands such 
as VCAM-1 (vascular cell adhesion molecule-1), ICAM-1 (intracellular adhesion molecule-1) 
and MAdCAM-1 (mucosal addressin cell adhesion molecule-1) as well as the unrelated 
protein E-cadherin. Moreover, leukocyte integrins can also recognize plasma proteins such as 
FN or the complement component iC3b. Minor exceptions with simultaneous characteristics 
of two integrin subclasses are the two heterodimers α9β1 and α4β1 as they recognize the 
LDV-motif in FN and they associate with receptors such as VCAM-1, an Ig-superfamily 
counter-receptor (Hynes 2002). 
Although the production of α and β chains within any given cell type may not be balanced, 
only intact heterodimeric integrins are found on the cell surface in cell-type dependent 
patterns – so called integrin profiles. Once integrins are bound to ECM components 
bidirectional signaling events influence cell adhesion, proliferation, migration, polarity, 
differentiation and survival, making integrins indispensible for the development and 
homeostasis of multicellular organisms (Sheppard 2000; Hynes 2002; Humphries et al. 2006). 
Due to the unique and essential features of integrins it is not surprising that there has been an 
evolutionary conservation in metazoans. Along with increasing organism complexity the 
Introduction 
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number of integrin heterodimers increased from two in Caenorhabditis elegans via five in 
Drosophila melanogaster to 24 in mammals with partially overlapping substrate specificity 
(Hynes 2002; Lowell and Mayadas 2012). 
 
2.2 Integrins have bidirectional signaling capacity 
The name “integrins” refers to their ability to integrate signals from the surrounding 
extracellular environment with the interior of the cell and vice-versa (Tamkun et al. 1986). 
This bidirectional signaling capacity is usually referred to as inside-out and outside-in 
signaling, respectively. 
2.2.1 Inside-out signaling 
2.2.1.1 Integrin conformation dictates receptor affinity 
The large extracellular integrin domain (>700 aa) binds ECM components and is linked via a 
transmembrane region (25-29 aa) to a short cytoplasmic tail (about 20-50 aa) (Arnaout et al. 
2005; Luo et al. 2007). In the case of inside-out signaling the intracellular adaptor molecules 
talin and kindlin initiate a conformational change of the extracellular integrin domain from a 
bent inactive state to an extended active state (Hynes 2002; Moser et al. 2009). This structural 
integrin modification was described as the switchblade model and involves an additional 
separation of the cytoplasmic tails and the transmembrane region to further upregulate 
receptor affinity (Luo et al. 2007) (Figure 2). 
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Figure 2: Conformational affinity regulation of integrins 
The bent inactive extracellular integrin domain (A) extends upon Talin and kindlin 
recruitment to the cytoplasmic integrin tail (B) followed by an additional increase in receptor 
affinity by transmembrane separation (C) (adapted and modified from Askari, 2009 (Askari et 
al. 2009)). 
 
Full integrin activation is prevented by a super weak salt bridge interaction between the α and 
the β subunit in the transmembrane region. In the platelet integrin αIIbβ3 for example, this 
salt bridge was identified to be established by the α subunit arginine 995 and the β subunit 
aspartic acid 723 (Hughes et al. 1996). Mutations of corresponding residues in the conserved 
GFFKR motif in α4 and αL disrupted the interaction and led to integrin activation (Lu and 
Springer 1997; Imai et al. 2008). However, an aspartic acid to alanine mutation of the salt 
bridge residue in the β1 cytoplasmic tail in mice did not show any obvious phenotype 
questioning the role of a putative salt bridge in vivo (Czuchra et al. 2006). Therefore, recent 
studies suggest an inner and outer membrane clasp (Lau et al. 2009) which might be primarily 
responsible for tail association with an only minor contribution of a potential salt bridge (Kim 
et al. 2009). Despite of these discrepancies regarding a mechanistic explanation, the overall 
Introduction 
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concept of transmembrane association and separation is widely accepted. Moreover, artificial 
models have demonstrated that integrin affinity downregulation is driven by transmembrane 
association (Lu et al. 2001; Luo et al. 2004; Zhu et al. 2008) and that upregulation is 
separation-dependent (Hughes et al. 1996; Gottschalk 2005; Li et al. 2005; Luo et al. 2005; 
Partridge et al. 2005). 
Conformational changes of the integrin molecule are mainly initiated by the recruitment of 
integrin activating molecules. However, there is an alternative mechanism of integrin 
activation, which is often used to verify defects in conventional integrin activation. Mg2+ or 
Ca2+ physiologically occupy metal-ion dependent adhesion sites (MIDAS) or related regions, 
whereas substitutions of these ions by Mn2+ cause a shift to the high affinity integrin 
conformation (Hynes 2002; Arnaout et al. 2005; Luo et al. 2007). 
2.2.1.2 Talin and Kindlin regulate integrin receptor affinity 
Receptor affinity of integrins is regulated by conformational changes initiated by the two 
FERM-domain-containing proteins talin and kindlin. 
Talin consists of a flexible rod domain and a FERM-domain-containing talin head domain 
(THD) (Rees et al. 1990; Calderwood et al. 2002; Garcia-Alvarez et al. 2003), which enables 
it to bind to the conserved membrane proximal NPxY motif as well as additional membrane 
proximal residues (Figure 3). 
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Figure 3: The talin molecule 
Depicted are the FERM-domain-containing THD and the flexible talin rod. The THD is 
composed of the F0- to F3-FERM-subdomains (adapted from Moser 2009 (Moser et al. 
2009)). 
 
Upon talin binding, cytoplasmic tails and transmembrane regions separate – a process that is 
referred to as the final common step in integrin activation (Tadokoro et al. 2003; Simonson et 
al. 2006; Lim et al. 2007; Nieswandt et al. 2007; Petrich et al. 2007). Whereas the 
phosphotyrosine-binding (PTB) F3-FERM-subdomain was described to be sufficient for β3 
integrin activation (Calderwood et al. 2002), a complete THD association is required for β1 
integrin activation (Bouaouina et al. 2008). Although the talin rod domain is not necessary for 
integrin activation, it plays a central role in focal adhesion (FA) formation and possibly also 
in integrin clustering by establishing connections to the actin cytoskeleton and by potential 
homodimerization via its second integrin binding site (Critchley and Gingras 2008; Zhang et 
al. 2008). Multiple studies have shown that a disruption of the NPxY motif in the cytoplasmic 
integrin domain inhibits talin binding and prevents integrin activation (Knezevic et al. 1996; 
Vinogradova et al. 2002; Ulmer et al. 2003; Wegener et al. 2007). Additionally, there is an 
autoinhibitory association between the talin head and rod domains, which functions as a 
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regulatory mechanism to prevent excessive integrin activation and which is disrupted by 
phosphatidylinositol-4,5-bisphosphate binding (Martel et al. 2001; Goksoy et al. 2008). Until 
today it is not entirely clear if phosphorylation of the integrin NPxY motif plays a role in the 
recruitment of talin to the cytoplasmic tail. In vivo studies on non-phosphorylatable β1 
integrins showed no obvious phenotype (Chen et al. 2006; Czuchra et al. 2006), while 
analogue mutations in the β3 tail resulted in mild bleeding defects (Law et al. 1999) and 
pathological angiogenesis (Mahabeleshwar et al. 2006). 
Recent studies revealed that there is an additional requirement of kindlin besides the essential 
integrin activator talin (Ma et al. 2008; Montanez et al. 2008; Ussar et al. 2008). The kindlin 
family consists of kindlin-1, which is mainly expressed in epithelial cells, kindlin-2, which is 
widely expressed, and the hematopoietic kindlin-3 (Jobard et al. 2003; Siegel et al. 2003; 
Ussar et al. 2006; Meves et al. 2009). The structure of kindlin resembles the THD with a PH 
(pleckstrin homology)-domain inserted into the F2-FERM-subdomain (Kloeker et al. 2004; 
Goult et al. 2009; Meves et al. 2009). As described for talin, kindlin uses its F3-FERM-
subdomain to bind to the distal NxxY motif and the adjacent threonines or serines depending 
on the β integrin subunit (Shi et al. 2007; Ma et al. 2008; Montanez et al. 2008; Moser et al. 
2008; Ussar et al. 2008; Moser et al. 2009) (Figure 4). 
Introduction 
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Figure 4: The kindlin molecule 
Depicted is the kindlin molecule with its N-terminus and the C-terminal F1- to F3-FERM-
subdomains including an inserted PH-domain in the F2-FERM-subdomain (adapted from 
Moser 2009 (Moser et al. 2009)). 
 
Functional consequences of defective kindlin-binding on integrin-mediated processes were 
demonstrated in in vivo knockout studies in mice. Loss-of-function mutations in human 
kindlin-1 are causative of a rare autosomal recessive skin disease characterized by congenital 
skin blistering, photosensitivity, progressive poikiloderma, cutaneous atrophy and potential 
skin cancer formation (Jobard et al. 2003; Siegel et al. 2003; Meves et al. 2009). While 
similar effects were also observed in kindlin-1-null mice, additional intestinal defects were 
more pronounced and caused perinatal death due to ulcerative colitis (Ussar et al. 2008). 
Interestingly, this gastrointestinal phenotype has later also been observed in humans (Sadler et 
al. 2006; Kern et al. 2007). Kindlin-2 deletion in mice results in early embryonic lethality due 
to severe adhesion and polarization defects on a defective BM at the peri-implantation stage 
(Montanez et al. 2008). Most likely, the severe consequences of kindlin-2 dysfunction are the 
reason why analogue mutations have not been identified in humans so far. Finally, kindlin-3 
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deletion in the hematopoietic system caused severe bleedings and defective platelet 
aggregation (Moser et al. 2008). Additionally, kindlin-3 was shown to be required for 
leukocyte adhesion and extravasation (Moser et al. 2009). Kindlin-3 mutations were identified 
to be responsible for a rare genetic leukocyte abnormality called leukocyte-adhesion 
deficiency (LAD) type III characterized by bleedings as well as defects in leukocyte adhesion 
and extravasation (Mory et al. 2008; Kuijpers et al. 2009; Malinin et al. 2009; Svensson et al. 
2009). 
2.2.1.3 Concepts of integrin activation 
Despite of a widely accepted synergistic integrin activation model including talin and kindlin, 
mechanistic details remain largely elusive. Although simultaneous binding is theoretically 
possible, there are also alternative concepts of sequential binding or integrin transactivation 
(Moser et al. 2009) (Figure 5). The transactivation concept refers to the binding of one 
integrin activator to one integrin heterodimer while the other activator binds an associated 
second heterodimer. 
Moreover there might also be substantial differences in the role of integrin activation for 
different integrin heterodimers. While the platelet integrin αIIbβ3 requires extremely fast 
activation upon vascular injury, β1 integrins in epithelial cells might tolerate slower changes 
in receptor affinity. All things considered, there is a widely accepted general concept of 
integrin activation. However, it is not entirely clear until today how the activation works in 
detail and if there are cell-type specific differences in receptor affinity modulation. 
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Figure 5: Potential concepts of integrin activation 
Depicted are three potential concepts of talin- and kindlin-mediated integrin activation 
including sequential binding (A), simultaneous binding (B) or transactivation (C) (adapted 
from Moser, 2009 (Moser et al. 2009)). 
 
2.2.2 Outside-in signaling 
Integrins possess bidirectional signaling capacity as they cannot only convey signals from the 
inside to the outside of the cell, as described for integrin activation, but also vice-versa from 
the outside to the inside. Due to a lack of any enzymatic activity integrins do not only 
establish connections to the actin cytoskeleton but they also recruit numerous adaptor proteins 
that modulate cell behavior like cell cycle stimulation via ERK and cyclin D1, inhibition of 
apoptosis via PI3-kinase, Akt and NFκB as well as shape, polaritiy and motility modulation 
via protein tyrosine kinases, phosphatases and members of the Rho family of small GTPases 
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(Luo et al. 2007; Legate et al. 2009; Lowell and Mayadas 2012). This network of adaptor 
proteins is usually referred to as integrin adhesome and comprises about 40 direct and 140 
indirect integrin binding proteins (Zaidel-Bar et al. 2007; Zaidel-Bar and Geiger 2010; 
Schiller et al. 2011) most of which are recruited to the β subunit (Legate et al. 2009). This 
highly complex network undergoes a continuous process of reorganization involving 
molecular assembly and disassembly. The major functions of this network are signal 
transduction and actin cytoskeleton interactions (Figure 6). This is mediated by direct 
integrin-binding proteins with actin-binding capability such as talin, α-actinin, filamin and 
tensin. However, this network is supplemented by additional actin-binding molecules such as 
vinculin, which are indirectly recruited to the tail via adaptor molecules. Although talin is 
capable of direct actin recruitment indirect connections via vinculin have also been described 
(Humphries and Humphries 2007; Legate et al. 2009). 
The actin cytoskeleton undergoes continuous reorganization processes initiated by Rho 
GTPase recruitment, a member of the Ras (rat sarcoma) superfamily. In humans there are 
over 22 Rho GTPases including the most prominent representatives RhoA, Rac1 (Ras-related 
C3 botulinum toxin substrate 1) and Cdc42 (cell division cycle 42). Rho GTPases are 
regulated by GEFs (guanine nucleotide exchange factor), GAPs (GTPase activating proteins) 
and GIDs (guanine nucleotide dissociation inhibitor) to allow highly dynamic regulations of 
not only actin dynamics, but also gene expression, membrane trafficking, microtubule 
dynamics, proliferation and cytokinesis (Hynes 2002; Jaffe and Hall 2005; Heasman and 
Ridley 2008). 
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Figure 6: Integrin outside-in signaling 
Integrins bind the ECM to establish dynamic actin cytoskeleton interactions and to convey 
signals by adaptor protein recruitment to their cytoplasmic tails (adapted and modified from 
Askari 2009 (Askari et al. 2009)). 
 
Since individual integrin-ligand interactions are relatively weak, multiple connections need to 
be established for proper ECM adhesion. This involves clustering of integrins into adhesive 
units in a synergistic process known as avidity. Based on size, morphology, localization and 
composition several types of adhesions can be distinguished in cultured cells including 
nascent adhesion (Choi et al. 2008), focal complexes (FCs), focal adhesions (FAs) and 
fibrillar adhesions (Geiger and Bershadsky 2001). Special adhesive structure such as 
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podosomes and invadopodia are cell-type specific and exclusively found in monocytic and 
tumor cells, respectively (Linder 2009). 
Furthermore integrins modulate growth factor signaling and trafficking, as described for the 
epidermal growth factor receptor (EGFR) or the fibroblast growth factor receptor (FGFR) 
(Walker et al. 2005), as well as lipid raft trafficking (del Pozo et al. 2005; Balasubramanian et 
al. 2007). Taken together integrins are much more than a purely mechanic link between the 
ECM and the actin cytoskeleton. Bidirectional signaling and actin dynamics make integrins 
indispensible for multiple cellular processes (Schwartz 2001; Hynes 2002; Ramsay et al. 
2007; Ulrich and Heisenberg 2009). 
 
2.3 Integrin trafficking 
Fundamental cellular processes such as cell adhesion, proliferation and migration do not only 
depend on bidirectional signaling but also on continuous integrin synthesis, internalization, 
recycling and degradation – a process called integrin trafficking (Figure 7). 
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Figure 7: Integrin trafficking 
(A) Integrin mRNA is transcribed in the nucleus and translated in ribosomes at the 
endoplasmic reticulum prior to exocytosis to the plasma membrane via the TGN. (B) Upon 
internalization into the endosomal compartment integrins are either recycled via the Rab4-
dependent short loop pathway or via the Rab11/ARF6-dependent long loop recycling pathway 
through the PNRC. (C) A minor proportion of integrins leaves this recycling machinery and 
enters ECSRT-mediated lysosomal degradation. 
 
2.3.1 Internalization 
In a continuous process integrin DNA is transcribed to acquire mRNA for ribosomal protein 
synthesis. These newly synthesized integrin polypeptides mature by various modifications 
such as glycosylations as they travel through the trans-Golgi network (TGN) to the cell 
surface where they exhibit their function as adhesion receptors (Figure 7A). Initial misfolding 
leads to proteasomal degradation (Romisch 2005). Integrins are internalized in a continuous 
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process, which is either clathrin- or caveolin-dependent or entirely independent of these two 
proteins (Mosesson et al. 2008; Caswell et al. 2009; Doherty and McMahon 2009; Grant and 
Donaldson 2009; Sorkin and von Zastrow 2009). There is substantial evidence that integrins, 
analogue to the EGFR, can use all of these three routes (Caswell et al. 2009; Shin et al. 2012) 
(Galvez et al. 2004; Pellinen et al. 2008; Shi and Sottile 2008). Even a specific integrin 
heterodimer can use different routes of endocytosis depending on localization, cell type and 
cell state (Caswell and Norman 2008; Caswell et al. 2009). There is contradicting evidence 
regarding the requirement of a functional NxxY motif for clathrin-mediated endocytosis 
(Vignoud et al. 1994; Pellinen et al. 2008). Multiple clathrin-adaptor proteins like HAX1 
(Ramsay et al. 2007), Dab/ Dab2 (Calderwood et al. 2003; Chao and Kunz 2009; 
Teckchandani et al. 2009) and Numb (Calderwood et al. 2003; Nishimura and Kaibuchi 2007) 
have been identified as integrin binding partners in previous studies, while the latter two were 
shown to bind integrin NxxY motifs. Moreover there is contradicting evidence with respect to 
the activation state of internalized integrins. Internalization of active (Nishimura and Kaibuchi 
2007; Chao and Kunz 2009) as well as inactive integrins or activation-independent 
endocytosis (Teckchandani et al. 2009) is controversially discussed. One study suggests that 
in certain cell types an association of integrins with neuropilin 1 (NRP1) selectively promotes 
active integrin internalization (Valdembri et al. 2009). The authors suggest this mechanism to 
be crucial for ECM reorganization. It is known that α5β1 integrins bind monomeric FN and 
expose hidden domains by mechanical force transduction, which is essential for FN 
polymerization (Zhong et al. 1998). Localized integrin trafficking is substantial for focal 
adhesion reorganization and strengthening (Shi and Sottile 2008; Valdembri et al. 2009). 
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2.3.2 Recycling 
Upon internalization integrins are routed back to the plasma membrane, a process called 
integrin recycling (Figure 7B). Only a minor proportion of integrins leaves this cycle for 
lysosomal degradation. This highly efficient spatiotemporally regulated integrin recycling 
does not only save energy, which would otherwise be necessary for synthesis, but also favors 
a continuous redistribution of integrins being an essential prerequisite for directed migration 
(Bretscher 1996; Caswell and Norman 2006; Caswell et al. 2007; Pellinen et al. 2008), 
adhesion, polarity, proliferation and signaling (Caswell and Norman 2006; Caswell et al. 
2009; Sorkin and von Zastrow 2009; Scita and Di Fiore 2010). Detailed analyses, especially 
of cell migration, could identify additional contributing factors such as Rho GTPase signaling 
and interactions with growth factor receptors (White et al. 2007; Caswell et al. 2008; 
Reynolds et al. 2009). 
Recent studies demonstrated that integrin trafficking is rather a local event than being an en 
masse redistribution of integrin molecules. Shortly after internalization local accumulations of 
integrins were visualized in sorting endosomes at the leading edge of the cell (Pierini et al. 
2000), where also clathrin-mediated endocytosis was shown to be highly pronounced 
(Rappoport and Simon 2003) Afterwards a majority of endosomes enters the perinuclear 
recycling compartment (PNRC) (Laukaitis et al. 2001; Nishimura and Kaibuchi 2007) before 
being transported back to the plasma membrane. Both, newly synthesized as well as recycling 
integrins were shown to be mainly targeted to the cell front (Hopkins et al. 1994; 
Schmoranzer et al. 2003; Prigozhina and Waterman-Storer 2004). Having this in mind it 
seems rather unlikely that an en masse redistribution of integrins is the driving force of cell 
migration. Instead, local integrin reorganization seems to focus signaling events at the leading 
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edge. However, a Rab21-driven en masse relocalization of integrins does occur during cell 
division and the following repolarization of the cell (Pellinen et al. 2006; Pellinen et al. 2008). 
Yet, this has to be considered as an exception since similar en masse integrin redistributions 
have not been observed in any other cellular process. 
Integrin trafficking is regulated by a number of small Rab (Ras-associated binding) proteins 
of the family of small GTPases, which function as molecular switches in vesicular transport 
(Jones et al. 2006; Chia and Tang 2009; Stenmark 2009). So far approximately 70 Rab 
GTPases have been identified (Mitra et al. 2011) most of which are involved in intracellular 
protein trafficking. After Rab21-mediated integrin endocytosis two competing routes target 
integrins back to the plasma membrane either via the Rab11 and/or ADP ribosylation factor 6 
(ARF6) dependent long loop pathway through the PNRC or the Rab4-dependent short loop 
recycling pathway through early endosomes (Caswell and Norman 2006; Jones et al. 2006; 
Pellinen and Ivaska 2006; Caswell and Norman 2008) (Figure 7B). Remarkably, integrins can 
co-recycle with other receptors as it has been shown for the EGFR-1 in a Rab-coupling 
protein (RCP) mediated process (Caswell et al. 2008). 
2.3.3 Degradation 
Upon internalization integrins are mainly recycled back to the plasma membrane. However, a 
minor part is targeted for lysosomal degradation (Caswell et al. 2009; Lobert et al. 2010). 
Like almost all transmembrane receptors, including the extensively studied receptor tyrosine 
kinases (RTKs) and the EGFR, integrins are ubiquitinated prior to endosomal sorting complex 
required for transport (ESCRT)-mediated lysosomal degradation (Lobert et al. 2010). To this 
end, integrins are separated from cytoplasmic adaptor proteins by sorting them into 
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intraluminal vesicles (ILVs) in multivesicular bodies (MVBs). Afterwards these fuse with the 
lysosomal compartment and exposed integrins to degrading enzymes such as proteases and 
lipases (Figure 7C). 
Numerous studies attribute ESCRT-mediated protein degradation a central role in cell 
migration. For example, a knockout of the ESCRT-1 component TSG101 (Tumor 
susceptibility gene 101) impairs cell migration and leads to intracellular integrin accumulation 
(Lobert et al. 2010) as well as reduced FAK and Src signaling (Tu et al. 2010). Since integrins 
were reported to be lysosomally degraded (Lobert et al. 2010) the reduced cell migration is 
likely to be caused by defective integrin trafficking in these cells. Moreover, regulated 
integrin degradation has been identified as a substantial factor in integrin signaling 
(Huveneers and Danen 2009). 
Despite extensive research on integrin trafficking and deep insights in the recycling 
machinery, there is only little known about integrin degradation. Yet, tightly regulated 
integrin degradation is indispensible for multiple cellular processes and proper integrin 
homeostasis. There is increasing evidence that integrin internalization is more than just a 
simple starting point of integrin recycling and reorganization. Most likely, internalization 
targets integrins to a point of quality control from which functional integrins enter the 
recycling process, while defective molecules are targeted for lysosomal degradation. An 
alternative concept of lysosomal integrin trafficking was described by Lobert et al. identifying 
this pathway as a potential mechanism to degrade integrin-bound FN in the sense of constant 
ECM remodeling and subsequent recycling of free integrins back to the plasma membrane 
(Lobert et al. 2010). 
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2.4 The family of PX-domain proteins and sorting nexins 
The whole pathway of protein trafficking from synthesis via endocytosis and recycling to 
degradation requires a tightly controlled sorting machinery to assure proper protein targeting. 
Recently, scientists found that there is more to integrin trafficking than pure protein sorting, 
since it was also reported to be necessary for other cellular processes such as cell signaling 
(Sorkin and von Zastrow 2009; Scita and Di Fiore 2010).  
Essential factors in the molecular sorting process are members of the phox homology (PX)-
domain protein family whose salient feature is to bind phosphatidylinositol phospahte 
(PtdInsP) lipids of cytoplasmic vesicles. Until today there are 49 members to this family 
including the most prominent representatives known as sorting nexins (SNXs) (Seet and Hong 
2006; Cullen 2008). The name SNX was coined by Kurten et al. as they described SNX1 for 
the first time and it became the name of a whole protein family with at least 50% sequence 
homology to the PX-domain of SNX1 (Teasdale et al. 2001; Worby and Dixon 2002). Based 
on this rather arbitrary classification Teasdale et al. suggest to assign all new PX-domain 
proteins a successive SNX number (Teasdale and Collins 2012). The unique features of PX-
domain proteins make them indispensible in membrane trafficking, signaling, membrane 
remodeling and in cell organelle trafficking. Almost all PX-domain proteins bind PtdIns3P, a 
lipid which is typically found in the limiting membrane of endosomal vesicles and therefore 
recruits PX-domain proteins to these compartments (Teasdale and Collins 2012). 
Co-incidental detection of membrane lipid binding domains such as bin/amphiphysin/rvs 
(BAR), band4.1/ezrin/radixin/moesin (FERM) or pleckstrin homology (PH) proteins as well 
as other cargo proteins such as transmembrane receptors or Rabs can increase specific binding 
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to certain cellular structures (Carlton and Cullen 2005; Teasdale and Collins 2012). With 
respect to integrin trafficking SNX17, SNX27 and SNX31 are highly interesting since they do 
not only posses a PX-domain but also a FERM-domain, which is typically known to bind 
NxxY motifs as found in the cytoplasmic β1 integrin tail (Ghai et al. 2011; Teasdale and 
Collins 2012) (Figure 8). Previous studies demonstrated the role of SNX17 in endosomal 
trafficking of different transmembrane receptors such as the low density lipoprotein receptor 
related protein 1 (LRP1) (Stockinger et al. 2002; van Kerkhof et al. 2005; Betts et al. 2008; 
Donoso et al. 2009), the low density lipoprotein receptor (LDLR) (Stockinger et al. 2002; 
Burden et al. 2004), P-selectin (Florian et al. 2001; Williams et al. 2004; Knauth et al. 2005) 
and the amyloid precursor protein (APP) (Lee et al. 2008). However, the molecular 
mechanism how SNX17 functions in sorting these cargo proteins is not entirely clear. For the 
LDL receptor it was shown that SNX17 promotes endocytosis (Stockinger et al. 2002) and 
recycling back to the plasma membrane (van Kerkhof et al. 2005; Donoso et al. 2009). Yet, in 
the case of P-selectin it prevents lysosomal degradation (Knauth et al. 2005). An association 
with the retromer complex transporting endosomal proteins to the TGN has not been 
identified for SNX17 so far as opposed to most other SNX protein family members. From a 
clinical point of view SNX17 came into the focus of interest due to its inhibition of APP 
processing to the toxic amyloid Aβ (Lee et al. 2008), which is a major component in the 
pathogenesis of the Alzheimer’s disease. Besides its typical association as a FERM domain 
protein with NxxY motifs, SNX17 binds also Krit1 (krev-interaction trapped 1), which 
promotes endosomal recruitment (Czubayko et al. 2006) as well as SH3-domain proteins such 
as Src-related tyrosin kinases and PLCγ1 (phospholipase C γ1) (Wu et al. 2007) (Figure 8). 
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Figure 8: Molecular structure and interactions of SNX17 
Depicted is a model of SNX17 with annotated previously reported binding partners. 
 
 
2.5 Integrins in a medical context 
Integrins are not only of fundamental interest in basic research but they also have broad 
implications in medical contexts. Every single integrin subunit has now been deleted in mice 
providing substantial knowledge about the specialized functions of integrins in vivo (Sheppard 
2000). The phenotypes resulting from these deletions are grouped according to the most 
effected organ system. 
2.5.1 Vasculature 
Interactions of integrins with growth factor receptors such as VEGF and of endothelial cell 
integrins with the ECM are of critical importance in vascular formation during embryonic 
development and adult blood vessel integrity (Weis 2007; McCarty 2009) as well as in 
pathological angiogenesis in neoplastic tissues or chronic inflammation. The most prominent 
subclass of integrin adhesion receptors in vasculogenesis are the RGD-motif recognizing 
heterodimers, like integrin α5β1 with its ligand FN (Astrof and Hynes 2009). Therefore, it is 
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not surprising that severe mesodermal defects and poor vascularization of the yolk sac and the 
embryo itself were described in both α5 integrin knockout mice (Yang et al. 1993) and even 
more pronounced in FN-depleted mice (Hynes 2007). β1-null mice suffer from dramatic 
defects in gastrulation with early peri-implantation lethality due to the loss of many integrin 
heterodimers (Fassler and Meyer 1995; Stephens et al. 1995). Interestingly, Tie2-cre-mediated 
deletion of the β1 integrin subunit in endothelial cells displays a very similar phenotype to α5-
null mice underlining the predominant role of endothelial α5β1 integrin in vascular 
morphogenesis (Carlson et al. 2008). 
In pathological vessel formation as present in tumor growth and wound healing the VEGF- 
and VEGF receptor-interacting αvβ3 integrin plays a central role (Brooks et al. 1994; Soldi et 
al. 1999; De et al. 2005; Mahabeleshwar et al. 2006). This makes αvβ3 integrins an ideal 
therapeutic target in tumor neovascularization with only minor interference with physiological 
vascularization mainly maintained by α5β1 integrins. In line with this, first successes have 
been described in animal tumor models using a monoclonal αvβ3-blocking antibody (Brooks 
et al. 1994). Knockout studies on αv integrins have identified its role in vascular parenchyma 
organization with severe vascular malformations and hemorrhages, predominantly present in 
the brain (Bader et al. 1998; McCarty et al. 2002). Consistent with this localized function, 
endothelial deletion of αv integrins has no effect on vascular development (McCarty et al. 
2005). Similar defects have been observed upon β8 integrin deletion pointing towards a 
predominant role of the αvβ8 heterodimer (Zhu et al. 2002; Proctor et al. 2005). 
The vascular defect in α4-null mice arises later as a consequence of a failed chorion-allantois 
fusion during placentation with accompanying cardiac abnormalities, most likely due to the 
deficient interactions with VCAM-1 (Kwee et al. 1995; Yang et al. 1995; Grazioli et al. 
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2006). Moreover, α9β1 integrins and their interactions with VEGF-C and VEGF-D have been 
identified to be essential for lymphatic vessel development (Huang et al. 2000; Vlahakis et al. 
2005; Bazigou et al. 2009). 
2.5.2 Nervous system 
Within the central nervous system (CNS) the eye is the best-studied organ with respect to 
integrin-related functions. Lens development depends on proper FN, collagen and LN 
assembly by functional interactions with the corresponding integrin heterodimers, especially 
those containing a β1 subunit (Simirskii et al. 2007; Walker and Menko 2009). Moreover, 
integrins guide the migration of neuronal precursor cells along glial fibers as required for 
retina development (Milner and Campbell 2002). Associations of cortical structures along the 
developing meningeal BM dictate the inner architecture of the brain by functional β1 integrin-
LN interactions (Miyagoe-Suzuki et al. 2000; Graus-Porta et al. 2001). Similarly, neuronal 
synapse stability depends on β3 integrin heterodimers (Benson et al. 2000). Neural crest 
migration during the development of the peripheral nervous system (PNS) depends on β1 
integrin heterodimer-directed migration along the embryonic ECM, while functional 
abnormalities in this system lead to abnormal nerve arborization, Schwann cell defects and 
impaired neuromuscular junction differentiation (Feltri et al. 2002; Pietri et al. 2004; Denda 
and Reichardt 2007). Additionally, αvβ5 integrins on retinal pigment epithelial cells were 
identified as phagocytic receptors to mediate uptake of shed photoreceptor particles while β5-
null mice lack this clearing system and develop age-related blindness (Nandrot et al. 2004). 
Integrin signaling has also been implicated to effect neuronal survival in degenerative 
diseases such as Parkinson’s or Alzheimer’s disease. And finally and most obvious, integrins 
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have also been associated with neuroinflammatory disease such as multiple sclerosis as they 
are absolutely essential for immune response (Denda and Reichardt 2007). 
2.5.3 Immunity 
The immune system is probably the best-studied field of integrin biology and most functional 
concepts are based on observations in this system. For example processes such as 
bidirectional integrin signaling were first described and analyzed in leukocytes and platelets. 
The major task of integrins in this process is to localize the immune response to the site of 
inflammation (Evans et al. 2009). Especially leukocyte exit from the vasculature into the 
lymph nodes or the site of inflammation and injury are critically dependent on integrins. The 
leukocyte adhesion cascade with subsequent diapedesis is initiated by selectin-mediated 
adhesion and rolling as well as chemokine-induced integrin activation. Afterwards high-
affinity integrins lead to full cell arrest on the endothelium and finally diapedesis (Ley et al. 
2007). However, this model is extremely simplified and for example also α4β1 integrin-driven 
rolling has been observed (Berlin et al. 1995). Nevertheless, the overall concept is well 
established and β2-deficient mice show severe immunodeficiency in support of this model 
(Scharffetter-Kochanek et al. 1998). Similarly, patients lacking the β2 integrin subunit suffer 
from a disease called leukocyte adhesion deficiency (LAD) type I characterized by recurrent 
infections without pus formation, wound healing defects and variable forms of infectious 
gingivitis (Etzioni 2010). Recently, LAD type III, a disease characterized by bleedings, 
immunodeficiency and osteopetrosis-like bone defects, has also been associated with integrins 
and their inside-out signaling capacity. Activation of β1, β2 and β3 integrins in hematopoietic 
cells is critically dependent on kindlin-3 recruitment to the distal cytoplasmic integrin tail 
which was identified to be mutated in these patients (Mory et al. 2008; Kuijpers et al. 2009; 
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Malinin et al. 2009; Moser et al. 2009; Svensson et al. 2009). A lack of β1 integrins on blood 
cells impairs hematopoietic stem cell colonization to the fetal liver or spleen during 
development (Potocnik et al. 2000) and causes defects in leukocyte migration to peripheral 
organs (Sixt et al. 2006). 
Although it is widely accepted that immune cell migration is absolutely dependent on integrin 
function, studies on mice lacking all leukocyte integrins questioned this simplistic concept. 
Dendritic cells lacking all these integrin adhesion molecules migrated normally through the 
skin and into lymph nodes where they initiated immune response by antigen presentation 
(Lammermann et al. 2008). Therefore, we have to question the overall implication of integrins 
in immune cell migration, although they remain indispensible for multiple processes such as 
leukocyte extravasation. 
Beyond the role of integrins in immune cell migration, they have also been described to be 
involved in outside-in signaling and to stimulate T-cell receptor (TCR) response (Pribila et al. 
2004; Abram and Lowell 2009; Smith-Garvin et al. 2009). Analogue modulations were 
observed in neutrophils (Berton et al. 1996). Interestingly, this activation of leukocyte 
integrins is practically even more important than the simple migratory processes. For 
example, bleedings induced by endotoxin and chemokine exposure in a model of 
thrombohemorrhagic vasculitis can be minimized in the absence of αMβ2 integrins (Hirahashi 
et al. 2006). Although αMβ2-deficient neutrophils are recruited to the site of vascular 
inflammation they do not release proteases. This is due to a defective recognition of 
complement deposits and subsequently reduced activation by outside-in signaling events. 
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Therapeutic concepts of autoimmune disorders include antagonists for two integrins. First, the 
monoclonal antibody (mAb) natalizumab that binds the α4 subunit is approved for the 
treatment of multiple sclerosis (MS) (Rice et al. 2005) and Crohn’s disease (Targan et al. 
2007). Second, there is the mAb efalizumab targeting αLβ2 (also known as LFA1) with 
indications in severe psoriasis treatment (Frampton and Plosker 2009). However, these two 
antibodies have severe potentially fatal side effects due to their immune suppressive 
properties leading to progressive multifocal leukoencephalopathy (PML) (Warnke et al. 
2010). Therefore, natalizumab was withdrawn from the market in 2005 and reintroduced due 
to its high efficacy in reducing the rate of relapses in MS in 2006. However, efalizumab was 
withdrawn from the market in 2009 and never reintroduced (Major 2010). 
And last but not least, various infectious agents have been reported to utilize integrins and 
subsequent co-internalization to enter the intracellular milieu (Fitzgerald et al. 2006; Stewart 
and Nemerow 2007). 
2.5.4 Platelets and thrombosis 
The first process to be associated with integrins was thrombosis. Upon vascular injuries, the 
platelet integrin αIIbβ3 is exposed to thrombotic stimuli and becomes activated – a process 
which is regard as the initial step of clot formation (White et al. 2004). Subsequently, 
integrins mediate platelet-platelet interactions by FN bridges between each other (Coller and 
Shattil 2008). This serves as an essential mechanism to prevent blood loss. However, 
excessive thrombus formation might cause a heart attack or stroke. 
Absence of the β3 subunit as an essential component of the platelet αIIbβ3 integrin leads to 
severe bleedings in mice (Hodivala-Dilke et al. 1999). The corresponding disease in humans 
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is usually referred to as Glanzmann’s thrombasthenia (George et al. 1990; Lefkovits et al. 
1995; Bennett 2005; Wegener et al. 2007; Harburger et al. 2009; Moser et al. 2009; Moser et 
al. 2009). 
This detailed knowledge about integrins in platelet aggregation drove the development of new 
therapeutic strategies. In the 1990s, αIIbβ3 integrin was the first one to be pharmacological 
inhibited by three different intravenous drugs namely the antibody fragment abciximab and 
the small-molecule inhibitors eptifibatide and tirofiban, while the development of orally 
active antagonists failed so far (Chew et al. 2001). Initial indications were the prevention of 
ischemic events in patients with acute coronary syndromes and those undergoing 
percutaneous coronary intervention (Bonaca et al. 2009; Cox et al. 2010). However, ADP 
receptor antagonists such as clopidogrel or prasugrel mainly dominate the global 
pharmaceutical market, while indications for integrin inhibitors are limited to high-risk 
patients. 
2.5.5 Skin 
Integrins link keratinocytes to the underlying BM via α6β4 integrin-containing 
hemidesmosomes and to each other directly (Watt 2002). Conditional Kreatin5- or Keratin14-
driven deletion of β1 integrin heterodimers in the skin leads to incomplete perinatal lethality 
with some mice surviving up to 6 weeks (Brakebusch et al. 2000; Raghavan et al. 2000). 
These mice lose their hair completely and show poor keratinocyte proliferation and fibrosis 
due to chronic inflammation. Interestingly, a loss of either α2β1 or α3β1integrin alone can be 
compensated by the other heterodimer indicating redundant functions (DiPersio et al. 1997; 
Chen et al. 2002). Inducible β1 integrin deletions in the skin or in cell culture revealed an 
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increase in proliferation and differentiation suggesting a suppressive role of β1 integrins under 
these circumstances (Grose et al. 2002; Muller et al. 2008). Functional β1 integrin signaling is 
of critical importance in the skin since a loss of function mutation of the epithelial-expressed 
integrin activator kindlin-1 has been identified to cause a rare genetic skin disease in humans 
called Kindler syndrome characterized by blistering, progressive poikiloderma and potential 
skin cancer formation (Meves et al. 2009). 
Defects in α6β4 integrins lead to dermal and epidermal separation and alter immune response 
by influencing TGFβ signaling (DiPersio et al. 2000). In line with these functional 
abnormalities in the hemidesmosome integrin, a very similar phenotype can also be observed 
in humans in a rare skin disease called junctional epidermolysis bullosa syndrome (EBS) 
characterized by extreme blistering and skin fragility. The EBS is frequently combined with 
an intestinal occlusion, termed pyloric atresia, leading to early postnatal lethality. Occlusions 
of the esophagus, urethra or pylorus result from detachment and subsequent fusion of 
epithelial linings (Hogg and Bates 2000; Wilhelmsen et al. 2006). 
2.5.6 Lung 
Similar to epithelial abnormalities in the skin, defects in integrin receptors such as the α3β1 
heterodimer lead to pulmonary impairments due to defective BM formation and poor cell 
adhesion (Kreidberg et al. 1996). The RGD-motif-binding αvβ6 integrin is typically expressed 
in epithelial cells of the lung, skin and kidney where it binds FN and associates with the 
latency associated peptide (LAP) which is responsible of preventing newly secreted TGFβ to 
bind to its receptor (Aluwihare and Munger 2008). Interactions of αvβ6 integrins with LAP 
lead to TGFβ dissociation and subsequent binding to its receptor on epithelial cells and 
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pulmonary macrophages. This initiates a strong anti-inflammatory response which prevents 
lung injury by inappropriate macrophage activation (Takabayshi et al. 2006). Therefore, mice 
lacking either the β6 subunit or TGFβ develop a strong pulmonary inflammation with 
accompanying emphysema formation (Huang et al. 1996; Morris et al. 2003). Additionally, 
these mice are not capable of surfactant recycling due to defects in macrophage functionality 
(Koth et al. 2007). Similarly, αvβ8 integrin-TGFβ interactions regulate the proliferative and 
inflammatory response of epithelial cells in the upper airway (Fjellbirkeland et al. 2003). 
Finally, αvβ5 binds and activates VEGF, which increases vascular permeability and leads to 
pulmonary edema formation after ischemia-reperfusion or hyperventilation (Su et al. 2007). 
This process is driven by actin stress fiber formation and cell retraction – a phenotype that is 
absent in αvβ5 integrin deficient mice. 
2.5.7 Muscles and skeleton 
In muscle tissue integrin focal adhesion sites allow the establishment of actin/myosin 
structures (Sparrow and Schock 2009). It is clear that a number of RGD-motif-, LN- and 
collagen-binding integrins are involved like the α1β1 or the α2β1 heterodimer. However, the 
exact individual heterodimers are less well defined. α5β1 integrins were associated with a 
progressive skeletal muscle dystrophy with diffuse muscle cell degeneration and apoptosis 
due to defective bidirectional signaling (Taverna et al. 1998). Additionally, a loss of the 
ECM-integrin connection leads to a special form of apoptosis usually referred to as anoikis. 
Interestingly, in neoplastic tissues or in the case of metastasis formation, cells can overcome 
this process of anoikis and survive (Frisch and Screaton 2001). LN receptors such as 
dystrophin, utrophin or α7β1 integrin link LN of the ECM to the muscle cell actin 
cytoskeleton with partially overlapping functions and reciprocal compensation (Campbell 
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1995). Abnormalities in this anchorage lead to a well-known disease called Duchenne’s 
muscular dystrophy – a progressive myocyte degeneration caused by a loss of dystrophin. A 
similar but less pronounced impairment was reported in α7-null mice (Hayashi et al. 1998). 
These mice presented an additional defect in neuromuscular junctions as well as in muscle-
tendon junctions indicating a role of α7 integrins in these structures (Nawrotzki et al. 2003). 
This shows that although LN receptors are dispensable for muscle development, they play a 
major role in the maintenance of myocyte integrity and function. 
Skeletal development is primarily dependent on RGD-motif and collagen receptors. 
Osteoclast signaling events initiated by αvβ3 integrin-osteopontin and bone sialoprotein 
interactions regulate bone morphogenesis by continuous remodeling processes mediated by 
bone-resorbing proteases (Ross and Teitelbaum 2005). Therefore, a lack of β3 integrins or 
downstream signaling proteins like Src kinases causes an excess of bone material called 
osteopetrosis (Horton et al. 2003; Faccio et al. 2005; Ross and Teitelbaum 2005). However, in 
patients with Glanzmann’s thrombasthenia, which is characterized by a lack of β3 integrins, 
this phenotype has not been observed, most likely due to a compensating overexpression of 
β1 integrins (Horton et al. 2003). Nevertheless minor skeletal abnormalities or bone cysts 
might be present in these patients. Collagen binding integrins such as α10β1 and α11β1 only 
have a minor effect on musculoskeletal development characterized by dental development 
abnormalities and retarded growth of long bones in the limbs due to cartilage defects in the 
growth plate (Bengtsson et al. 2005; Popova et al. 2007). 
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2.5.8 Kidney 
Multiple β1 integrins have been reported to be involved in renal development and kidney 
diseases. For example, a lack of the α8β1 heterodimer or its renal ligand nephronectin leads to 
frequent complete renal agenesis due to the disability of epithelial ureteric bud (UB) cells to 
invade into the surrounding mesenchyme and subsequently form the metanephric kidney 
(Muller et al. 1997; Brandenberger et al. 2001; Linton et al. 2007). The α8β1 integrin-
nephronectin interaction functions not only as a guiding structure for directed migration, but 
also induces bidirectional signaling and especially growth factor signaling of the TGFβ 
superfamily (Costantini and Shakya 2006). α3β1 integrin is another heterodimer involved in 
renal development with special implications in the branching morphogenesis of the renal 
tubular collecting system (Kreidberg et al. 1996; Liu et al. 2009). Since an entire deletion of 
all β1 integrins causes a much more severe phenotype than deletions of the individual 
heterodimers mentioned above, it is very likely that additional integrin heterodimers dictate 
renal development and function (Zhang et al. 2009). Interestingly, a late deletion of β1 
integrins does not impair renal development but negatively effects renal response upon injury 
in adult mice, most likely do to defective growth factor interactions (Zhang et al. 2009). 
Finally, renal glomerular structures composed of mesangial cells and podocytes interacting 
with the BM in fine vascular capillaries are dependent on β1 integrins as selective 
knockdowns in podocytes cause massive proteinuria and rapid death (Kanasaki et al. 2008). 
Moreover, glomerular injury, for example as a result of immune complex deposition, leads to 
mesangial cell proliferation induced by integrin-growth factor interactions (Kagami and 
Kondo 2004). In a mouse model of Alport’s syndrome with mice lacking α1β1 integrins, the 
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proliferative response and the subsequent glomerular injury could be dramatically reduced 
(Cosgrove et al. 2000). 
2.5.9 Cancer 
Carcinogenesis is highly dependent on integrins with their unique feature to modulate all steps 
of cancer progression including detachment from and invasion of the ECM, blood vessel 
infiltration, extravasation in distant organs and metastasis formation (Brooks et al. 1996; 
Felding-Habermann et al. 2001; Mercurio et al. 2001; Bates et al. 2005; Makrilia et al. 2009). 
Moreover, they are also involved in signaling events of neoplastic tissues by RTK 
modulation. Therefore, it is not surprising that integrins have attracted considerable attention 
as potential targets for cancer therapy and diagnosis (Kenny et al. 2008; Axelsson et al. 2010). 
Being a known trigger for cell survival (Chudakova et al. 2008), scientists identified the 
highest therapeutic potential in targeting αvβ3 integrins (Nemeth et al. 2007). There are 
numerous ongoing clinical trials with multiple αvβ3 inhibitors for different indications: The 
mAb etaracizumab for melanoma (Hersey et al. 2010; Moschos et al. 2010) and solid tumors 
(Delbaldo et al. 2008), the orally active non-peptide MK 0429 for prostate cancer (Rosenthal 
et al. 2010) as well as the cyclic peptide cilengitide for glioblastoma (Reardon et al. 2008; 
Stupp et al. 2010) and other brain cancers (MacDonald et al. 2008) which has just recently 
entered phase III trials as the first anti-integrin therapy for cancer (Carter 2010). However, 
first in vivo studies with the αvβ3 integrin inhibitor cilengitide showed disappointing results, 
which is most likely due to increased recycling of other integrin heterodimers as well as RTKs 
(Nisato et al. 2003; Maubant et al. 2006; Tucker 2006; Stupp and Ruegg 2007; Caswell et al. 
2009). 
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Another integrin of interest with respect to cell survival, migration and angiogenesis is α5β1 
integrin (Kim et al. 2000; Kim et al. 2000). Therefore, the development of the α5-specific 
antibody volociximab for solid tumors was initiated (Ricart et al. 2008; Ng et al. 2010). A 
potential co-administration of αvβ3 as well as α5β1 inhibitors might optimize the effects on 
tumor angiogenesis (Laurens et al. 2009). 
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3 Aims of the thesis 
3.1 Aim 1: Generation of a β1 TT/AA mouse model 
Integrins are adhesion receptors with fundamental functions in cell adhesion, proliferation and 
migration. These functions critically depend on modifications in receptor affinity by the 
integrin-activating proteins talin and kindlin. Mutations in their binding sites have been 
identified to cause severe impairments in cellular functions. In this thesis an in vivo mouse 
model was established to analyze the effects of a defective kindlin-binding site by introducing 
a threonine 788/789 to alanine mutation in the β1 integrin cytoplasmic tail. 
Aim1: Generation of a mouse model to analyze the in vivo consequence of a β1 TT/AA 
mutation, which was described to dramatically reduce kindlin-binding in vitro. 
 
3.2 Aim 2: SILAC-screen for new β1 integrin binding partners 
Detailed analyses of the β1 TT/AA mutation in vivo revealed substantial defects in integrin 
function due to reduced integrin activation as predicted by previous in vitro studies as well as 
due to dramatically reduced integrin expression by increased lysosomal degradation. 
Aim 2: To identify new cytoplasmic β1 integrin binding partners a SILAC-screen was 
applied. 
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3.3 Aim 3: Characterization of SNX17 in β1 integrin trafficking and degradation 
We identified SNX17 as a new β1 integrin binding partner. This PX-domain protein has 
previously been associated with endosomal sorting of transmembrane receptors and has a 
potential role in integrin trafficking. 
Aim 3: Analysis of SNX17-mediated integrin trafficking and lysosomal integrin degradation. 
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4 Methods 
 
The method section was adapted and modified from Böttcher and Stremmel et al. 2012 
(Bottcher et al. 2012). 
 
 
4.1 Mouse strains 
Mice were basically generated as described previously (Czuchra et al. 2006). The loxP-
flanked neomycin cassette was inserted upstream of β1 integrin exon 16 and the following 
point mutations were introduced using the AlteredSites II in vitro mutagenesis system 
(Promega): threonines 788 and 789 to alanines (β1 TT/AA) and tyrosine 795 to alanine (β1 
Y795A). These targeting constructs were introduced into R1 ES cells and clones that 
underwent homologous recombination were isolated. BamHI digested genomic DNA was 
tested with an external and internal probe by Southern blotting and injected into blastocysts to 
generate germline chimeras. These mice were intercrossed with deleter-Cre transgenic mice 
(Betz et al. 1996) to obtain heterozygous mutants. Homozygous mutants were embryonic 
lethal. For fibroblast isolations heterozygous mutants were intercrossed with mice carrying a 
floxed β1 integrin gene (β1 floxed) (Brakebusch et al. 2000). Genotyping was performed by 
Southern blotting or PCR using DNA isolated from tail biopsies. All animal studies were 
approved by the Regierung von Oberbayern. 
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4.2 Antibodies 
The following antibodies were used for western blotting (WB) and immunofluorescence (IF): 
Antibody Company (Clone) Catalogue # Dilution Used for 
Actin Sigma A-2066 1:3000 WB 
β1 integrin Chemicon (MB1.2) MAB1997 1:400 IF 
β3 integrin Millipore (EP2417Y) 04-1060 1:1000 WB 
β-catenin Sigma C2206 1:800 IF 
E-cadherin Zymed (ECCD-2) 13-1900 1:200 IF 
Laminin111 Abcam ab30320 1:400 IF 
EEA1 BD Transduction Laboratories 610457 1:100 IF 
GAPDH Calbiochem (6C5) CB1001 1:5000 WB 
Kindlin-2 Sigma K3269 1:1000 WB 
Lamp1 By L. Huber (Medical University Innsbruck, Austria)  1:100 IF 
Paxillin BD Transduction Laboratories (349) 610051 1:400 IF 
SNX17 Proteintech 10275-1-AP 1:1000 WB 
Talin-1 Sigma (8d4) T3287 1:1000 WB 
Transferrin 
receptor Invitrogen (H68.4) 13-6800 1:1000 WB 
Ubiquitin Cell Signaling (P4D1) 3936 1:1000 WB 
Kindlin-1 Homemade (Ussar et al. 2006)  1:5000 WB 
Kindlin-3 Homemade (Ussar et al. 2006)  1:5000 WB 
β1 integrin Homemade (Azimifar et al. 2012)  1:10000 WB 
Phalloidin Molecular Probes A12379 and A22287 1:400 IF 
DAPI Sigma   IF 
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The following antibodies were used for flow cytometry: 
Antibody Company Clone  Catalogue # Dilution 
β1 integrin PE BioLegend HMbeta1-1 102207 1:400 
β1 integrin biotin BD Pharmingen Ha2/5 555004 1:400 
β1 integrin 9EG7 BD Pharmingen 9EG7 550531 1:100 
β3 integrin PE eBioscience 2C9.G3 12-0611 1:400 
β4 integrin PE Serotec 346-11A MCA2369 1:400 
α2 integrin FITC BD Pharmingen Ha1/29 554999 1:400 
α5 integrin PE BD Pharmingen 5H10-27 557447 1:400 
α5 integrin biotin BD Pharmingen 5H10-27 557446 1:400 
α6 integrin PE BD Pharmingen GoH3 555736 1:400 
αv integrin PE BD Pharmingen RMV-7 551187 1:400 
 
4.3 Plasmids and constructs 
The following point mutations were introduced into the corresponding cDNAs by site directed 
mutagenesis: β1 integrin (TT788/789AA, Y783A, Y795A, 8xKR (K752R, K765R, K768R, 
K770R, K774R, K784R, K794R, K798R), 8xKR+TT788/789AA), α5 integrin (4xKR 
(K1022R, K1027R, K1038R, K1042R)) and SNX17 (QW360/361AA). Stable cDNA 
expression was achieved by cloning of the following cDNAs into the retroviral expression 
vector pCLMFG or pLZRS: β1 integrin (wt, TT788/789AA, Y783A, Y795A, 8xKR, 
8xKR+TT/AA), human α5 integrin (wt, 4xKR, α5-eGFP) as well as mouse SNX17 (wt, Flag-
tagged, eGFP-tagged, and mCherry-tagged). Recombinant expression of GST-tagged SNX17, 
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wt SNX17 and SNX17 QW360/361AA cDNA was achieved by cloning into the pGEX-6P-1 
vector (GE Healthcare). Lamp1-mRFP, Rab7-mRFP vectors were obtained from J. Norman 
(Beaton Institute, Glasgow), Rab5a-GFP was provided by L. Huber (Medical University 
Innsbruck, Austria) and transiently expressed by transfection with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol. 
SNX17 expression was stably depleted by shRNAs: 5’-GTACATGCAAGCTGTTCGG-3’ 
(shSNX17-1), 5’-GATTGTGCTCAGAAAGAGT-3’ (shSNX17-2). Target sequences were 
introduced into the pSuper.Retro vector (OligoEngine, USA) to produce retroviral particles. 
To obtain a GFP-tagged kindlin-2, the kindlin-2 cDNA (Ussar et al. 2006) was ligated in 
frame with the GFP using SLIC cloning (Li and Elledge 2007). The CAG promoter, GFP-
fusion and SV40 polyA were flanked by ITR elements, thus co-transfection of this construct 
with a sleeping beauty SB100x expression vector (Mates et al. 2009) resulted in transposase 
mediated genomic integration of this DNA sequence. 
4.4 Cell lines 
Heterozygous β1 TT/AA mice were intercrossed with homozygous β1 floxed mice. Mouse 
embryonic fibroblasts (MEFs) were isolated from E9.5 embryos and immortalized by 
retroviral transduction of the SV40 large T antigen. Cells were cloned by low-density plating 
and subsequent picking. The floxed β1 integrin allele was removed by adenoviral Cre 
transduction. Disruption of the β1 allele and expression of the β1 TT/AA were checked by 
PCR. To generate β1-null rescue cell lines, β1 wt or β1 mutant variants were virally re-
expressed in β1-null fibroblasts derived from adenoviral Cre transduced floxed β1 parental 
cells. 
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Fibroblasts homozygous for floxed kindlin-1 and -2 genes were isolated from kidneys of 21 
day-old double-floxed mice (whose generation will be described elsewhere). After 
immortalization by retroviral transduction of the SV40 large T antigen, cells were cloned by 
limiting dilutions. The floxed kindlin alleles were removed by adenoviral Cre transduction to 
obtain kindlin-1 and -2 double-null cells (provided by M. Widmaier). 
4.5 Transient and stable transfection/transduction 
Cells were transiently transfected with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. To generate stable cell lines, VSV-G pseudotyped retroviral vectors 
were produced by transient transfection of HEK293T (human embryonic kidney) cells. Viral 
particles were concentrated from cell culture supernatant as described (Pfeifer et al. 2000) and 
used for infection. 
4.6 Embryo isolation and histological analysis 
For whole-mount analyses and bright field images, staged embryos (E6.5 to E9.5) were 
dissected in ice-cold PBS. For histological analysis, decidua swellings were isolated, fixed in 
4% paraformaldehyde overnight and embedded in paraffin. Sections were stained with 
haematoxilin and eosin or antibodies as indicated. 
4.7 Whole-mount immunohistochemistry 
Embryos were dissected in cold PBS and fixed in 4% paraformaldehyde (PFA) for 2 hours at 
4°C. Samples were incubated in 0.5% NP-40/PBS for 20 minutes and in PBSST (0.1% 
Triton-X, 5% BSA in PBS) for 2 hours at 4°C for permeabilization. Staining was performed 
by incubation with primary overnight at 4°C followed by the secondary antibody overnight at 
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4°C. Nuclei were stained with DAPI solution for about 30 minutes. Finally, embryos were 
dehydrated by increasing methanol concentrations, cleared in benzyl alcohol/benzyl benzoate 
(1:2) and imaged with a confocal microscope (DMIRE2; Leica) using Leica Confocal 
Software (version 2.5 Build 1227). After imaging embryos were rehydrated for genotyping by 
PCR. 
4.8 ES cells and EBs 
ES cells were isolated and cultured as previously described (Montanez et al. 2007). Briefly, 
ES cells were isolated from the inner cell mass of E3.5 embryos called blastocysts and 
cultured on a monolayer of growth-inactivated MEFs (feeder cells) (Talts et al. 1999) in the 
presence of LIF to prevent ES cell differentiation. 
EBs were generated as previously described (Montanez et al. 2007). ES cells were trypsinized 
and separated from feeder cells by repetitive platings. Afterwards small ES cells aggregates of 
three to four cells were formed with the help of a fine-tip Pasteur pipette. These aggregates 
were subsequently cultured in simple untreated petri dishes in LIF-free ES cell medium to 
allow EB formation for approximately 5 days. Afterwards EBs were used for bright field 
images or stainings with antibodies as indicated. 
4.9 Metabolic labeling 
80% confluent cells were incubated for 30 min at 37°C in methionine/cysteine-free labeling 
media containing 10% dialyzed FBS and pulse-labeled for 30 min at 37°C in labeling medium 
containing 35S-methionine/cysteine (200 µCi/10 cm plate, EasyTag Express 35S Protein 
Labeling Mix, PerkinElmer). Afterwards, the cells were either immediately harvested (time 0) 
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or chased for 4 h, 8 h and 22 h in regular growth medium containing 10% FBS. Cells were 
lysed in IP buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 0.1% sodium 
deoxycholate, 1 mM EDTA and protease inhibitors) prior to incubation with β1 integrin 
antibodies for 1h on ice, followed by incubation with Protein G sepharose (Sigma) for 2 h at 
4°C for β1 immunoprecpiptation. After several washes with lysis buffer proteins were eluted 
from the beads by boiling with Laemmli sample buffer and subjected to SDS-PAGE. The gels 
were fixed, dried and exposed to film. 
4.10 Turnover of surface integrins 
The half-life of surface proteins was determined by biotinylation. Fibroblasts were grown to 
80% confluence, washed twice in cold PBS and surface-biotinylated with 0.2 mg/ml sulfo-
NHS-LC-biotin (Thermo Scientific) in PBS for 45 min at 4°C. Afterwards cells were washed 
with cold PBS to remove excessive biotin prior to incubation in regular growth medium for 0, 
5, 10 and 15 h at 37°C. Cells were lysed in IP buffer (50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1% Triton X-100, 0.1% sodium deoxycholate, 1 mM EDTA and protease inhibitors) 
and biotinylated proteins were pulled down with streptavidin-Sepharose (GE Healthcare). 
After three washes with lysis buffer, samples were analyzed by SDS-PAGE and western 
blotting. For capture ELISA, cells were lysed in 100 µl of lysis buffer (75 mM Tris, 200 mM 
NaCl, 7.5 mM EDTA and 7.5 mM EGTA, 1.5% Triton X-100, 0.75% Igepal CA-630 and 
protease inhibitors). 
4.11 Integrin trafficking assays 
Integrin trafficking assays were performed as described previously (Roberts et al. 2001). Cells 
were grown to 80% confluency and pre-incubated with serum free medium for 45 min. 
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Afterwards cells were washed with ice-cold PBS, surface-labeled with 0.13 mg/ml sulfo-
NHS-SS-biotin (Thermo Scientific) for 30 min at 4°C and washed again with ice-cold PBS to 
remove excessive biotin. Labeled surface proteins were internalized in serum-free medium at 
37°C for different time points. The remaining surface label was stripped with sodium 2-
mercaptoethanesulfonate (Mesna, Sigma) for 30 min at 4°C. Afterwards Mesna was quenched 
with iodoacetamide (IAA, Sigma) for 20 minutes at 4°C. Cells were washed with PBS and 
lysed in 100 µl of lysis buffer (75 mM Tris, 200 mM NaCl, 7.5 mM EDTA and 7.5 mM 
EGTA, 1.5% Triton X-100, 0.75 % Igepal CA-630 and protease inhibitors). The amount of 
biotinylated integrins was quantified by capture ELISA. 
For recycling assays, internalization was performed for 30 min and the remaining surface 
label was stripped with Mesna. Afterwards cells were incubated in regular growth medium 
containing 10% FBS for different time points at 37°C followed by a second stripping and 
subsequent quenching with IAA. Finally, the remaining β1 integrin biotin label was measured 
in lysed cells by capture ELISA. 
4.12 Capture ELISA 
Maxisorb 96-well plates (Life Technologies) were coated overnight with anti-β1 integrin 
antibody (MAB1997, Chemicon) in carbonate buffer at 4°C. Plates were washed with PBS 
and unspecific binding was blocked by 5% BSA in PBS/0.1% Tween-20 (PBS-T) for 2 h at 
RT. Cell lysates (50 µl each) were added to the wells and incubated overnight at 4°C to 
capture integrins. Following extensive washes with PBS-T, plates were incubated with 
streptavidin-HRP in 1% BSA in PBS-T for 1 hour at 4°C. Biotinylated β1 integrin was 
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detected after several washing steps by chromogenic reaction with ABTS peroxidase substrate 
(Vector Laboratories). 
4.13 Selective immunoprecipitations 
Selective isolation of β1 integrins on the cell surface and in endocytic vesicles was achieved 
by immunoprecipitation. Cell surface β1 integrins of living cells were labeled with a rabbit 
anti-β1 integrin antibody (homemade, 1:1500) for 1 h on ice and subsequently washed with 
ice-cold PBS to remove unbound antibody. Then, cells were incubated for 20 min in medium 
with or without 0.5 mM primaquine to inhibit integrin recycling to the cell surface (Roberts et 
al. 2001). After washing with PBS cells were lysed in IP buffer (50 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate, 1 mM EDTA and protease 
inhibitors) and cleared by centrifugation. β1 integrin immune-complexes were pulled down by 
incubation with protein G Sepharose (Sigma) for 2 h at 4°C. After several washes with lysis 
buffer, proteins were subjected to SDS-PAGE and western blot analysis. 
4.14 SILAC-based peptide pull-downs 
Pull-downs were performed as previously described (Meves et al. 2011) with the following 
cytoplasmic tail peptides: β1 wt tail peptide (758-798: 
HDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK-OH), β1 TT/AA tail 
peptide (HDRREFAKFEKEKMNAKWDTGENPIYKSAVAAVVNPKYEGK-OH), β1 
Y795A tail peptide (HDRREFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKAEGK-
OH), a scrambled peptide 
(EYEFEPDKVDTGAKGTKMAKNEKKFRNYTVHNIWESRKVAP-OH) and α5 peptide 
(KLGFFKRSLPYGTAMEKAQLKPPATSDA-OH). All peptides were desthiobiotinylated. 
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Prior to use, peptides were immobilized on 75 µl Dynabeads MyOne Streptavidine C1 (10 
mg/ml, Invitrogen). 
Cell lysates were generated with Mammalian Protein Extraction Reagent (Thermo Scientific) 
from fibroblasts cultured in the presence of normal or L-13C615N4-arginine (Arg10)-, L-
13C615N2-lysine (Lys8)-labeled medium. 1 mg of unlabeled or Arg10-, Lys8-labeled 
supernatant was incubated with either control or β1 peptide overnight at 4 °C. After washing 
with lysis buffer beads of corresponding peptide pairs were combined and proteins were 
eluted by incubating the beads in 16 mM biotin (Sigma-Aldrich) in PBS (pH 7.0) for 30 min 
at 30 °C followed by precipitation with cold acetone at −20°C overnight. The protein pellet 
was dissolved in SDS-PAGE sample buffer and separated on a 4–15% gradient SDS-PAGE 
gel. The gel was stained with Coomassie using the Gel Code Blue Safe Protein Stain reagent 
(Thermo Scientific) and used for mass analysis. 
4.15 Expression and purification of recombinant proteins 
Plasmids encoding GST-SNX17 or GST-SNX17QW/AA were transformed into BL21(DE3) 
Arctic Express Escherichia coli. One colony was grown in a 5 ml starter culture overnight at 
37°C, which was used to inoculate a 500 ml culture. Once the 500 ml culture reached 
OD600=0.6, protein expression was induced with 1 mM IPTG and the cells were grown for 3 h 
at 30°C. Cells were pelleted, washed once with PBS, lysed in TBS (50 mM Tris HCl, with 
150 mM NaCl, pH 7.4) containing protease inhibitors (Protease Inhibitor Cocktail Tablets, 
Merck), sonicated with a tip sonicator on setting “3” for 30 seconds 3 times, and thereafter, 
incubated with 100 µg/ml Lysozyme (Sigma) and 50 µg/ml DNaseI (Sigma) at 4°C for 3 
hours. Lysates were centrifuged with 14000 rpm at 4°C for 20 min. Supernatants were then 
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incubated with 1 ml glutathione Sepharose beads (GST-binding resin, Novagen) for 3 h at 
4°C. GST-tagged proteins were bound and eluted according to the manufacturer’s instruction.  
Plasmid encoding for His-tagged kindlin-2 was transformed into BL21 T1 pRARE cells. 
Supernatants were generated as described above and then incubate with His-Select Ni Affinity 
gel (Sigma) for 2.5 h at 4°C. His-tagged kindlin-2 eluted was eluted from the beads and 
subjected to gel filtration to further purify the recombinant protein. 
For pull-downs, synthetic peptides were immobilized on 20 µl Dynabeads My One 
Streptavidine C1 (10 mg/ml, Invitrogen) for 3 h at 4°C, incubated with 2% BSA in 
Mammalian Protein Extraction Reagent (Thermo Scientific) for 30 minutes to block 
unspecific binding prior to adding 50 ng recombinant GST-tagged SNX17 protein and further 
incubation on a rotator for 2h at 4°C. For competition experiments, 50 ng GST-SNX17 and 
500 ng His-kindlin-2 or 500 ng BSA were incubated with the tail peptides for 3 h at 4°C. 
After 3 washes with RIPA buffer, proteins were eluted from the beads by boiling with 80 µl 
SDS-PAGE sample buffer for 5 minutes, separated by SDS-PAGE gel and blotted with 
SNX17 antibody. 
4.16 qRT-PCR 
RNA was isolated from cells using the RNeasy mini kit (Qiagen) and 1 µg of total RNA was 
transcribed into cDNA using the iScript-cDNA Synthesis kit (Bio-Rad). Quantitative PCR 
assays were performed with the iCycler-iQ (Bio-Rad) using SYBR green and the following 
primers: β1 integrin-fwd (5’-atgccaaatcttgcggagaat-3’), β1 integrin-rev (5’-
tttgctgcgattggtgacatt-3’), β3 integrin-fwd (5’-ccacacgaggcgtgaactc-3’), β3 integrin-rev (5’-
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cttcaggttacatcggggtga-3’), GAPDH-fwd (5'-tcgtggatctgacgtgccgcctg-3'), GAPDH-rev (5'-
caccaccctgttgctgtagccgtat-3'). 
4.17 Immunofluorescence 
For immunostaining, cells were cultured on glass coated with 10 µg/ml FN (Calbiochem). For 
the detection of endosomes, cells were fixed with 4% PFA/PBS for 15 minutes on ice, washed 
with PBS and permeabilised with 0.01% saponin/PBS for 10 minutes on ice. Cells were 
blocked with 3% BSA/PBS for 1 hour followed by incubation with the primary antibody in 
3% BSA/0.01% saponin/PBS overnight at 4°C. After several washes with PBS, the 
fluorescently labeled secondary antibodies were incubated for 1 hour at RT in the dark. For 
other stainings, cells were fixed with 4% PFA/PBS for 15 minutes on ice and permeabilized 
with 0.2% TritonX-100/PBS for 10 minutes on ice. After fixation and permeabilization, the 
cells were incubated with 3% BSA in PBS for 1 hour followed by incubation with the primary 
antibody for 1 hour at RT or overnight at 4°C. Secondary antibodies were incubated for 1 
hour at RT. 
To determine the endocytic trafficking of β1 integrins from the cell surface by surface 
labeling, cells were washed with ice-cold PBS and incubated with an anti-β1 integrin antibody 
(HMbeta1-1, BioLegend) for 30 min on ice. Then, cells were washed again to remove 
excessive antibody. Surface-bound antibody was allowed to internalize for different time 
points at 37°C in regular growth medium. At each time point, the samples were washed with 
cold PBS and the remaining antibody at the cell surface was removed by two acid washes (0.2 
M acetic acid/0.5 M NaCl/PBS) for 2 min on ice. Subsequently, the cells were fixed, 
permeabilized and stained as described above.  
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Images were collected at RT by confocal microscopy (DMIRE2; Leica) with a 63x/1.4 
objective using the Leica Confocal Software (version 2.5, build 1227) or collected with an 
AxioImager Z1 microscope (Zeiss) with a 63x/1.4 oil objective. 
4.18 Time-lapse video microscopy of cell spreading and migration 
Cell spreading and single-cell migration assays were done as described (Montanez et al. 
2007). Briefly, 250,000 cells were plated on a FN-coated six-well plate and immediately 
imaged by live cell microscopy to determine spreading kinetics for indicated time points. 
Afterwards, adherent cells were monitored to analyze cell migration. Cell spreading was 
additionally measured with cells seeded on FN-coated glass slides, fixed with 4% 
paraformaldehyde at 37°C at indicated time points and stained with phalloidin-Alexa488 for 
F-actin. Images were taken with an AxioImager Z1 microscope (Zeiss) with a 20x objective 
and the spreading area was calculated using MetaMorph 7 imaging software (Molecular 
Devices).  
For single-cell migration the acquired images were analyzed using the manual tracking plugin 
of ImageJ and the Chemotaxis and Migration Tool (v2.0) of the QWT project. 
Cell wounding assays were performed with confluent monolayers of cells cultured in FN-
coated 6-well dishes. Cells were serum-starved overnight before wounds were applied with a 
200 µl plastic micropipette followed by thorough washing with PBS. Wound closure was 
imaged in serum-free medium at 15 min intervals overnight. The acquired images were 
analyzed using the manual tracking plugin of ImageJ and the Chemotaxis and Migration Tool 
(v2.0) of the QWT project. 
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Images of live cells were recorded at 37°C and 5% CO2 on a Zeiss Axiovert 200 M (Zeiss) 
equipped with 10x/.3, 20x/.4 and 40x/.6 objectives, a motorized stage (Märzhäuser) and an 
environment chamber (EMBL Precision Engineering) with a cooled CCD camera (Roper 
Scientific). Image acquisition and microscope control were carried out with MetaMorph 
software (Molecular Devices). 
4.19 Statistics 
Statistical analysis was performed using the GraphPad Prism software (version 5.00, 
GraphPad Software). Statistical significance was determined by the unpaired t-test or Mann-
Whitney U-test as indicated. Results are expressed as the mean ± SD if not indicated 
otherwise. 
4.20 Figures and figure legends 
Figures and figure legends were adapted and modified from Böttcher and Stremmel et al. 
2012 (Bottcher et al. 2012). 
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5 Results 
5.1 Early embryonic lethality by β1 integrin TT788/789AA and Y795A mutations 
The threonines 788/789 and the tyrosine 795 in the distal NxxY motif of the murine β1 
integrin tail are essential for kindlin binding and their disruption leads to severe functional 
integrin defects (Ma et al. 2008; Moser et al. 2008; Ussar et al. 2008). Therefore, we 
established an in vivo mouse model in which we substituted these amino acids by alanines 
causing massive impairments in early mouse development. While heterozygous mice 
developed normally, their intercrosses failed to produce living offspring (TT/AA: +/+: 35%, 
[TT/AA]/+: 65%, [TT/AA]/[TT/AA]: 0%, N=100; Y795A: +/+: 33%, [Y795A]/+: 67%, 
[Y795A]/[Y795A]: 0%, N=100). Timed-matings revealed extremely malformed or resorbed 
embryos on day 7.5 of embryonic development (E7.5) (+/+: 25%, [TT/AA]/+: 53%, 
[TT/AA]/[TT/AA]: 17%, resorbed: 5%, N=36) with defects in cell polarity, laminin111 
(LN111) distribution and cavitation (Figure 9A, B). Due to almost identical abnormalities in 
β1 TT/AA and β1 Y795A mice, we focused our work on the β1 TT/AA mutation. 
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Figure 9: β1 TT/AA mutation causes early embryonic lethality 
(A) Bright field images of E7.5 embryos with and without implantation chambers. (B) Left 
and central panels show whole-mount immunostainings of E7.5 embryos for β1 integrin (red) 
and LN111 (green). Nuclei were counterstained with DAPI (blue). Right panels show 
haematoxilin and eosin (HE) stainings of E7.5 embryo sections. em, embryo; de, decidua; ac, 
amniotic cavity; am, amnion; al, allantois; ch, chorion; ec, ectoplacental cone; fg, foregut; hg, 
hindgut; ex, exocoelomic cavity. Scale bars 100 µm. (C. Stremmel) 
 
To further analyze the in vivo effects, we isolated embryonic stem cells (ES cells) from 
blastocysts of β1 wild type (β1 wt) and littermate homozygous TT/AA (β1 TT/AA) mice. 
These ES cells were subsequently used to generate so-called embryoid bodies (EBs) in vitro, 
mimicking the early embryonic development in the pre-implantation period. After 2-4 days in 
suspension culture β1 wt ES cells formed first EBs consisting of an outer layer of primitive 
endoderm on a basement membrane (BM) with an undifferentiated core in the center, which 
differentiated in a pseudostratified ectoderm surrounding a central cavity by day 4-6. β1 
TT/AA ES cells formed compact cell aggregates surrounded by a discontinuous BM with 
single endodermal cells attached to it. These aggregates did neither show a polarized 
distribution of β-catenin, E-cadherin or F-actin nor a central cavity (Figure 10A, B). 
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Figure 10: Defective β1 TT/AA embryoid body formation 
(A) Upper panels show bright field images of EBs on the 5th day of suspension culture. Lower 
panels show cryo sections of EBs on the 5th day of suspension culture stained for β1 integrin 
(red) and LN111 (green). Nuclei were counterstained with DAPI (blue). (C) Cryo sections of 
EBs on the 5th day of suspension culture stained for β-catenin (red), E-cadherin (red), F-actin 
(red) and LN111 (green). Nuclei were counterstained with DAPI (blue). Scale bars 100 µm 
(A), 50 µm (B). (C. Stremmel) 
 
The analysis of β1 TT/AA ES cells revealed significant adhesion defects in culture on feeder 
cells (Figure 11A) as well as a dramatic reduction of the mature β1 integrin form (125 kDa), 
while the expression of talin-1 und kindlin-2 was unaffected (Figure 11B). These results 
highly correlated with fluorescence activated cell sorting (FACS) experiments, showing a 
reduction of β1 surface expression down to about 40%. Corresponding integrin α subunits, α5 
and α6, were similarly reduced, while β3 and αv levels were unchanged (Figure 11C). We 
used a 9EG7-epitope-recognizing antibody to study the activation state of β1 integrins. In line 
with previous studies demonstrating the requirement of an intact kindlin-binding site for 
proper integrin activation (Montanez et al. 2008), we found clearly reduced integrin activation 
levels in β1 TT/AA ES cells, which could be normalize by manganese treatment (Figure 
11D). Moreover, we performed quantitative real-time PCR (qRT-PCR) analyses and found 
significantly elevated β1 mRNA levels in TT/AA ES cells, indicating that the reduced surface 
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expression was not due to insufficient transcription (Figure 11E). These defects had also 
functional consequences as β1 TT/AA ES cells showed significant adhesion defects on ECM 
substrates (Figure 11F). Similar results regarding integrin expression and activation were 
observed in β1 Y795A ES cells. 
 
Figure 11: Reduced expression and activation of β1 TT/AA ES cells 
(A) Bright field images of ES cell colonies on feeder cells. (B) Western blot for β1 integrin, 
Talin-1, Kindlin-1, Kindlin-2 and actin of ES cell lysates including a control lane for Kindlin-
1 from a wt keratinocyte lysate. (C) Expression of integrin subunits in ES cells determined by 
FACS (mean±SD, n=4, *P=0.0134, **P=0.0011, ***P<0.0001). (D) Integrin activation on ES 
cells measured by 9EG7 binding and corrected for total β1 integrin expression (mean±SD, 
n=4, ***P=0.0003). (E) Expression of β1 integrin mRNA in ES cells measured by 
quantitative real-time PCR (n=2). (F) Adhesion assay of ES cells on different substrates 
(mean±SD, n=3, **P<0.01 and ***P<0.005). P values: Student's t-test; ns=not significant. (C. 
Stremmel) 
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To test whether these effects could also be observed in other cellular systems, we compared 
β1 wt and β1 TT/AA or β1 Y795A fibroblasts with each other. The cell lines were generated 
in two different ways: On the one hand we generated β1-null fibroblasts from β1 floxed mice 
and rescued these with β1 wt, β1 TT/AA or β1 Y795A cDNAs (Figure 12A). On the other 
hand, we isolated littermate β1 flox/wt and β1 flox/TT/AA fibroblasts and removed the floxed 
allele by adenoviral Cre transduction (Figure 12B). Fibroblasts from both cell systems showed 
analogue results in all assays. 
 
Figure 12: Generation of fibroblast cell lines 
Scheme depicting the generation of β1 wt and β1 TT/AA fibroblasts. β1 wt and β1 TT/AA 
fibroblasts were either obtained by retroviral expression of β1 variants in β1-null cells (A) or 
by immortalization of fibroblasts from mouse embryos and subsequent adenoviral Cre 
transduction (B). ((A) R. Böttcher mainly contributed, (B) C. Stremmel) 
 
Despite elevated mRNA levels, the expression of mature β1 integrin (125 kDa) was clearly 
reduced in β1 TT/AA fibroblasts, while a relative increase in expression of the immature form 
(105 kDa) in relation to β1 wt cells was observed in western blot experiments (Figure 13A-E). 
Again, 9EG7 antibody binding was substantially reduced in mutant cells (Figure 13F). In 
summary, these observations indicate that TT/AA or Y795A mutations reduce β1 integrin 
expression by processing or turnover alterations. 
Results 
 67 
 
Figure 13: Characterization of β1 TT/AA fibroblasts 
(A, B) Surface expression of different α and β integrin subunits on β1 wt and β1 TT/AA 
fibroblasts determined by FACS (mean±SD, n=6 (A), n=4 (B), *P<0.05, **P=0.0022, 
***P<0.0001). (C, D) β1 integrin mRNA levels determined by qRT-PCR (mean±SD, n=3 
with two independent cDNAs, *P=0.015, **P=0.0032). (E) Western blot analysis of fibroblast 
cell lines with antibodies against β1 integrin and actin. (F) β1 integrin activation measured by 
9EG7 binding and corrected for β1 integrin expression (mean±SD, n=4; **P=0.0097). P 
values: Student’s t-tests, ns=not significant. (C. Stremmel) 
 
5.2 Integrin turnover is controlled by the distal β1 integrin tail 
The determinants of integrin surface expression are synthesis, maturation, surface 
presentation, endocytosis, recycling and degradation. Synthesis-related causes for the reduced 
integrin surface expression in β1 TT/AA mutants were excluded by mRNA expression 
analyses. Therefore, we investigated integrin maturation in its secretion pathway by pulsed 
labeling with 35S-methionine/cystein. According to the higher integrin synthesis rate in β1 
TT/AA fibroblasts we found a pronounced 105 kDa band representing the immature integrin 
in these cells. Yet, the relative decrease in band intensity for the immature integrin was 
comparable in β1 wt and β1 TT/AA fibroblasts indicating normal processing of the β1 
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integrin polypeptide despite of the introduced mutation. The significantly higher expression of 
immature integrin (105 kDa) in β1 TT/AA fibroblasts paired with longer absolute persistence 
of mature integrin (125 kDa) in β1 wt cells, provides clear evidence for mutation-related 
differences in integrin turnover (Figure 14). 
 
Figure 14: β1 TT/AA integrin maturation 
Pulse-chase analyses of β1 integrin maturation in cells expressing β1 wt or TT/AA integrins. 
Cells were collected and analysed by immunoprecipitation after metabolic labeling with 35S-
methionine/cysteine and chased for the indicated time points. Maturation curves show 
immature β1 integrin as a percentage of the total β1 integrin (right) and were drawn from 
densitometric scans of the autoradiograms (left). (R. Böttcher mainly contributed) 
 
Further analyses of integrin turnover were performed by internalization and recycling assays 
after surface labeling with cleavable biotin. In doing so, we found a dramatically reduced 
recycling rate back to the plasma membrane in β1 TT/AA fibroblasts, while internalization 
kinetics were unaffected (Figure 15A, B). To test whether the reduced recycling rate is due to 
increased integrin degradation, we used the lysosomal inhibitors chloroquine and bafilomycin 
or the proteasomal inhibitor MG132 respectively. While lysosomal inhibition rescued β1 
TT/AA surface expression including the corresponding α5 integrin subunit, proteasomal 
inhibition failed to rescue the defects (Figure 15C). 
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Figure 15: Reduced recycling and enhanced lysosomal degradation of β1 TT/AA 
integrins 
(A) Quantification of β1 integrin internalization in β1 wt- and β1 TT/AA-expressing cells by 
capture ELISA (mean±SD, n=4). (B) Quantification of β1 integrin recycling in β1 wt and β1 
TT/AA-expressing fibroblasts by capture ELISA (mean±SD, n=5, *P < 0.05 and **P < 0.01). 
(C) Western blot analysis of β1 wt- and β1 TT/AA-expressing cells treated with either a 
proteasome (MG132) or a lysosome inhibitor (chloroquine) for 20 h. Actin served as a 
loading control. ((A, B) C. Stremmel, (C) C. Stremmel/ R. Böttcher equally contributed) 
 
Degradation kinetics were quantified by surface labeling with biotin followed by streptavidin 
pull-downs and western blotting or capture ELISA, an experimental technique utilizing β1 
integrin antibody-coated ELISA plates. We measured integrin half-lives of about 20 hours for 
the wild type protein and of about 4-5 hours for the TT/AA mutant. The observed effects were 
specific for the β1 mutation, since turnover rates of β3 integrin or the transferrin receptor (Tfr) 
were unchanged (Figure 16A-C). Analogue experiments were performed for the tyrosine to 
alanine mutation in both β1 integrin NxxY motifs. While the β1 Y783A mutation in the 
membrane proximal NxxY motif did not influence integrin stability, the β1 Y795A mutation 
in the distal motif revealed a dramatic reduction in integrin stability comparable to the β1 
TT/AA mutant (Figure 16D). These results let us draw the following conclusion: Mutating the 
threonines 788/789 or the distal NxxY motif respectively, leads to a dramatic increase in 
integrin turnover and lysosomal degradation. 
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Figure 16: Lysosomal integrin degradation kinetics 
(A, B) Degradation of cell surface integrins was determined by biotinylating cell surface 
proteins and incubating for the indicated time points, followed by biotin pull-down and 
western blot analysis (A) or quantification by capture ELISA (mean±SD, n=4, ***P<0.0001) 
(B). (C) Lysosomal inhibition by bafilomycin prevents degradation of β1 TT/AA integrin. 
Degradation was measured by surface biotinylation and incubation of the cells for 14 h in the 
presence or absence of bafilomycin. (D) Degradation of β1 integrin mutants (wt, TT/AA, 
Y783A and Y795A) was determined by biotinylating cell surface proteins and incubating for 
0 h and 15 h followed by biotin pull-down and western blot analysis. P values: Student's t -
test. (R. Böttcher mainly contributed) 
 
5.3 Kindlin-2 regulates β1 integrin surface expression by β1 mRNA level alterations 
The two threonines 788/789 and the distal NxxY motif are essential for kindlin binding and 
mutations within this region dramatically reduce the binding (Ma et al. 2008; Moser et al. 
2008; Ussar et al. 2008). In line with a previous study (Harburger et al. 2009), we 
demonstrated that kindlin2-eGFP overexpression in β1 wt fibroblasts clearly increases β1 
integrin expression. Interestingly, this increase could not be observed in β1 TT/AA 
fibroblasts, which is most likely due to the preexisting mRNA upregulation in these cells 
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(Figure 17A). Vice versa, cells lacking kindlin-1 and -2 (Figure 17H) showed a clear 
reduction in β1 integrin surface expression (Figure 17B). These obvious correlations between 
kindlin and integrin expression drove us to perform internalization, recycling and stability 
assays in kindlin-2-overexpressing cells all of which not showing any differences when 
compared to β1 wt fibroblasts (Figure 17C-E). Similarly, kindlin-1 and -2 knockout cells were 
not altered in degradation kinetics (Figure 17F). Internalization and recycling assays were 
technically impossible due to poor adhesion on ECM substrates. Based on these experiments, 
we were able to exclude kindlin-related trafficking processes as causative for the alterations in 
integrin expression. However, qRT-PCR analyses of kindlin-2 overexpressing cells showed a 
significant increase in β1 mRNA levels revealing a conclusive explanation for the observed 
relation between kindlin and integrin expression (Figure 17G). 
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Figure 17: Kindlin-2-dependent regulation of β1 integrin surface levels 
(A) β1 integrin surface expression in β1 wt- and β1 TT/AA-expressing fibroblasts after 
overexpression of kindlin-2-eGFP determined by FACS (mean±SD, n=11, ***P < 0.0001). 
(B) β1 surface levels in control (Kind (f/f)) and kindlin-1 and -2-double-null (Kind(-/-)) 
fibroblasts determined by FACS (mean±SD, n=3, ***P < 0.0001). Quantification of β1 
internalization (C) and recycling (D) in β1 wt and β1 TT/AA cells with and without kindlin-2-
eGFP overexpression by capture ELISA (mean±SEM, n=8 (C) and n=10 (D)). (E, F) 
Quantification of surface β1 integrin stability in kindlin-2-eGFP-overexpressing (E) and 
Kind(-/-) cells (F). Degradation of cell surface β1 integrin was determined by biotinylating 
cell surface proteins and incubating for the indicated time points, followed by capture ELISA 
(mean±SD, n=4 (E), n=3 (F)). (G) β1 integrin mRNA expression in kindlin-2-eGFP-
overexpressing fibroblasts measured by quantitative real-time PCR (n=2). (H) Western blot 
analysis of cell lysates from platelets, keratinocytes and Kind (-/-) fibroblasts with antibodies 
against the three kindlin family members. Actin and GAPDH served as loading control. P 
values: Student's t-test, ns=not significant. ((A-D, G) C. Stremmel, (E, F, H) R. Böttcher 
mainly contributed) 
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5.4 SNX17 interacts with the TT788/789-Y795-motif in the cytoplasmic β1 integrin tail 
To clarify how the threonines 788/789 and the membrane distal NxxY motif regulate surface 
expression, recycling and degradation, we screened for a new interactor with the β1 integrin 
cytoplasmic tail. Therefore, we used the SILAC (stable isotope labeling by amino acids in cell 
culture) (Ong et al. 2002) method in combination with subsequent pull-down experiments 
with synthesized full-length cytoplasmic domains of β1 wt and β1 TT/AA integrins as well as 
a scrambled peptide to identify unspecific interactions. Afterwards we performed mass 
spectrometry-based proteomics (Mann 2006) and identified the known β1 integrin interactors 
talin-1 and -2, kindlin-2, Dab2 and ILK as well as the new binding partner SXN17. 
Simultaneous analyses for the β1 TT/AA peptide showed a massive reduction in kindlin-2- 
and SNX17-binding due to the introduced mutation (Figure 18A). 
SNX17 is a member of PX-domain proteins, which play a central role in endosomal 
trafficking and associate predominantly with PtdIns3P-rich membranes. Besides, SNX17 is 
characterized by a FERM-domain with a QW-motif in the F3-subdomain, which is also 
present in the famous integrin adaptor proteins talin and kindlin and typically binds NxxY 
motifs as there are two of them in the β1 integrin cytoplasmic tail (Tadokoro et al. 2003; Ghai 
et al. 2011). An important role of SNX17 in endosomal trafficking has already been 
demonstrated for the transmembrane receptors LDLR, LRP1, P-selectin and APP (Stockinger 
et al. 2002; Burden et al. 2004; Knauth et al. 2005; van Kerkhof et al. 2005; Lee et al. 2008). 
We confirmed our proteomics data in peptide pull-down experiments and detected kindlin-2 
and SNX17 binding to β1 wt, but not to β1 TT/AA, α5 or scrambled peptides (Figure 18B). 
Moreover, we used this experimental setting to show that SNX17 binding to β1 integrins is 
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direct and specific. We used recombinant wild type GST-SNX17 (GST-SNX17) and 
compared it to GST-SNX17 in which the QW-motif in the FERM-F3-subdomain was mutated 
to alanines (GST-SNX17QW/AA). In doing so, we detected SNX17 with the GST-SNX17 
peptide, while there was no binding detectable in case of the QW/AA mutation (Figure 18C). 
 
Figure 18: SNX17 binds the distal cytoplasmic integrin tail 
(A) Scatter plot of β1 wt tail peptide versus scrambled-peptide pull-down results. The log2 
SILAC ratio of proteins identified with at least 2 unique peptides in each mass spectrometry 
run is plotted as the forward pull-down (x axis) against the reverse labeling pull-down (y 
axis). Specific interaction partners show inverse ratios between forward and reverse 
experiment, grouping them into the upper left quadrant. Red dots indicate those proteins that 
failed to bind to the β1 TT/AA tail peptide in a separate experiment. (B) Western blot 
showing talin-1, kindlin-2 and SNX17 binding to the biotinylated peptides indicated. 
Wcl=whole-cell lysate. (C) Streptavidin-bead pull-down assay with the indicated biotinylated 
β1 integrin cytoplasmic tail peptides and recombinant GST-tagged SNX17 or a GST-tagged 
SNX17QW/AA. ((A) A. Meves mainly contributed, (B, C) R. Böttcher mainly contributed) 
 
Immunofluorescence experiments showed co-localization of the early endosomal marker early 
endosomal antigen 1 (EEA1) (Figure 19A) as well as with the transferrin receptor as a marker 
for recycling endosomes (Figure 19B), while we were not able to detect any co-localization 
with the lysosomal markers lysosomal-associated membrane protein 1 (Lamp1) (Figure 19C) 
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or Rab7 (Figure 19D). Furthermore co-localization of kindlin-2 and SNX17 was not detected, 
pointing towards a spatially separated binding to β1 integrins in different cellular 
compartments (Figure 19E). However, both proteins kindlin-2 and SNX17 compete for the 
same binding region in the distal cytoplasmic integrin tail (Figure 19J). 
Due to a lack of suitable antibodies, we used live-cell microscopy to visualize SNX17-
integrin co-localization. To this end, we preincubated our cells with fluorescent integrin 
antibodies and allowed receptor internalization for defined time periods. Afterwards, we 
successfully visualized co-localization of β1 integrin and SNX17 in SNX17-eGFP transfected 
cells (Figure 19F). Not surprisingly, SNX17 was also recruited to β1 TT/AA positive 
endosomes, although we excluded direct interactions of these proteins (Figure 19G). 
Therefore, this observation is most likely due to interactions with other cargo proteins in 
integrin-carrying endosomes as LRP1 for example. With the help of antibodies against the 
9EG7-epitope we visualized integrins in focal adhesions, but not in SNX17-positive 
endosomes suggesting a predominant binding to low-affinity conformation integrins (Figure 
19G). To demonstrate interactions also with endogenous proteins, we enriched endosomal β1 
integrins with the recycling inhibitor primaquine (van Weert et al. 2000) and co-precipitated 
this with endogenous SNX17. Also in the endogenous setting, the interaction was destroyed 
by the introduction of the β1 TT/AA mutation (Figure 19H). In summary, the new β1 
integrin-binding protein SNX17 associates with β1 integrins in the kindlin-binding region and 
is located in endosomes. 
Results 
 76 
 
Figure 19: SNX17 binds the distal cytoplasmic integrin tail in endosomes 
(A, C) Immunostaining of SNX17-eGFP-expressing cells with EEA1 (A), Tfr (B) and Lamp1 
(C) antibodies. Nuclei were counterstained with DAPI (blue). Correlation coefficient 
0.300±0.116 (EEA1), 0.032±0.121 (Tfr), 0.457±0.141 (Lamp1), mean±SD, n=44 (A), n=13 
(B), n=25 (C). (D) SNX17-eGFP-expressing cells were transfected with Rab7-mRFP and the 
fluorescence distribution was determined in living cells by spinning disk confocal 
microscopy. Stills of movies are shown (correlation coefficient Rab7-mRFP 0.454±0.106, 
mean±SD, n=15. (E) SNX17-mCherry-expressing cells were transfected with kindlin-2-eGFP 
and fluorescence distribution was determined in living cells by spinning disk confocal 
microscopy. Stills of movies are shown. (F) Localization of endogenous β1 integrin after 
surface labeling with an anti-β1 integrin antibody and internalization for 15 min in SNX17-
eGFP-expressing cells. The fluorescence intensity was determined in living cells by spinning 
disk confocal microscopy. A still of a movie is shown. In A to H, lower panels show an 
enlargement of the area indicated by the white rectangle. (I) Co-immunoprecipitation of 
endogenous β1 integrin and SNX17 from β1 wt- and β1 TT/AA-expressing cells pre-treated 
with or without primaquine. Wcl=whole-cell lysate. Scale bars 20 µm. (J) Streptavidin-bead 
pull-down assay with a biotinylated wild type β1 integrin cytoplasmic tail peptide and 
recombinant GST-tagged SNX17 and His-tagged kindlin-2. (R. Böttcher mainly contributed) 
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5.5 SNX17 controls recycling and stability of β1 integrins 
To analyze the function of SNX17 in integrin trafficking and/or degradation, we depleted 
SNX17 by retroviral expression of shRNAs (shRNA17-1 and shSNX17-2). This depletion 
caused of clear reduction of the mature integrin form in western blotting as well a 40% 
reduction in β1 integrin surface expression (Figure 20A, B). In line with our previous results, 
we were able to rescue this reduction by bafilomycin treatment. SNX17-depelted cells showed 
an excessive integrin degradation in western blotting as well as capture ELISA compared to 
control fibroblasts (shCtr). This degradation was specific since neither the Tfr nor β1 TT/AA 
integrins, which cannot bind SNX17, were affected by the SNX17-depletion (Figure 20D-F). 
Additionally, re-expression of shRNA-resistant SNX17 rescued the defects, while 
SNX17QW/AA failed in doing so (Figure 20C, G). Similar to β1 TT/AA cells, trafficking 
assays did not show any internalization defects in SNX17-depleted cells, despite of significant 
defects in integrin recycling. Therefore, we classify SNX17 as a promoter of integrin 
recycling back to the cell surface, which inhibits degradation (Figure 20H). 
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Figure 20: Depletion of SNX17 reduces surface expression of β1 integrins 
(A) Western blot analysis of control (siCtr) or two siSNX17-transfected cells (siSNX17-1 and 
siSNX17-2) treated with or without bafilomycin for 20 h. Actin served as loading control. (B) 
Quantification of β1 surface levels in control and SNX17-depleted cells determined by FACS 
(mean±SD, n=9, ***P < 0.0001). (C) β1 integrin surface levels in SNX17-depleted cells were 
restored by re-expressing siRNA-insensitive wt SNX17 but not with SNX17QW/AA 
(mean±SD, n=3, **P=0.0079). (D, F) Degradation of cell surface integrins was determined by 
biotin pull-down and western blot analysis (D) or capture ELISA (F) (mean±SD, n=5). (E) 
SNX17-depleted β1 TT/AA expressing cells were surface-biotinylated and incubated for the 
indicated time points before biotinylated proteins were pulled down with streptavidin-
Sepharose and analyzed by western blotting. (G) Western blot analysis of cell lysates derived 
from the indicated β1 integrin-expressing and SNX17-depleted cells. SNX17 levels were 
restored in the SNX17-depleted cell lines by re-expressing either siRNA-insensitive wt 
SNX17 or SNX17QW/AA. (H) Quantification of β1 integrin recycling in SNX17-depleted 
cells by capture ELISA (mean±SEM, n=7, ***P<0.0008). Note the strong reduction in the 
level of β1 integrin recycling after SNX17 depletion. P values: Student's t-test, ns=not 
significant. ((A, D-G) R. Böttcher mainly contributed, (B, C, H) C. Stremmel) 
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To further analyze the early endocytosis pathway, we surface-labeled integrins with 
fluorescent antibodies prior to internalization for different time points. After 10 minutes both 
β1 wt and β1 TT/AA fibroblasts showed an evenly distributed punctuated integrin pattern in 
the early endosomal compartment. After 30 minutes the fluorescent signal was clearly 
reduced in β1 wt cells, indicative for an effective recycling back to the plasma membrane. 
However, in β1 TT/AA and SNX17-depeleted cells the fluorescent signal co-localized with 
Lamp1, a marker for the lysosomal compartment. Therefore, we strengthened our conclusion 
that a functional β1 integrin-SNX17 interaction promotes integrin recycling and prevents its 
degradation (Figure 21). 
 
Figure 21: Immunostaining of lysosomal β1 integrin degradation 
Localization of endogenous β1 integrin after surface labeling with an anti-β1 integrin 
antibody and internalization for 10 and 30 min in β1 wt, β1 TT/AA and SNX17-depleted 
cells, respectively, treated with or without bafilomycin. Cells either expressed Rab5a-GFP or 
were fixed and stained with antibodies against Lamp1. Nuclei were counterstained with DAPI 
(blue). Scale bar 20 µm. (R. Böttcher mainly contributed) 
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Further analyses focused on the question whether SNX17 primarily promotes recycling or 
inhibits degradation of integrins. We performed recycling experiments with β1 wt and β1 
TT/AA or SNX-depleted cells in the presence or absence of bafilomycin. In doing so, we 
demonstrated that bafilomycin treatment can normalize the recycling defects as well as the β1 
integrin surface expression in both β1 TT/AA and SNX17-depleted cells to β1 wt levels 
(Figure 22A, D, E). Integrin antibody internalization assays showed that the previously 
described accumulation of integrins in the lysosomal compartment of mutant cells was 
abrogated by bafilomycin treatment (Figure 21). Additionally, we substituted all α5 and β1 
integrin cytoplasmic lysine residues by arginines (α5 4xKR, β1 8xKR±TT/AA) to prevent 
ubiquitin-mediated lysosomal degradation. While integrin internalizations was unaffected by 
the mutations, we could rescue the stability and recycling defects in β1 TT/AA fibroblasts by 
simultaneous expression of β1 8xKR+TT/AA and α5 4xKR (Figure 22B, C). Remarkably, 
expression of β1 8xKR+TT/AA alone did not fully rescue the defects, indicating that α5β1 
integrin degradation cannot only be mediated by the β but also by the α subunit. In this study, 
we show that SNX17 primarily prevents integrin degradation, while the effects on integrin 
recycling are secondary. 
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Figure 22: β1 TT/AA and SNX17 regulate lysosomal integrin degradation 
(A) β1 integrin recycling is restored to wt levels in β1 TT/AA cells treated with bafilomycin. 
The quantity of biotinylated β1 integrin remaining within the cells was determined by capture 
ELISA using β1 integrin-specific antibodies (mean±SEM, n=3). (B) Quantification of the 
stability of cell surface β1 integrins by capture ELISA. The indicated cell lines were surface 
biotinylated and incubated under starving conditions (mean±SD, n=3). (C) Quantification of 
β1 integrin recycling determined by capture ELISA. Cells express either α5 wt and β1 wt or 
α5β1 with K > R-mutant tails (mean±SEM, n=4). (D) Bafilomycin normalizes the recycling 
of β1 wt in SNX17-depleted cells. The quantity of biotinylated β1 integrin remaining within 
the cells was determined by capture ELISA using β1 integrin specific antibodies (mean±SEM, 
n=3). (E) Quantification of β1 surface levels by FACS in indicated cell lines treated for 8 h 
with and without bafilomycin (mean±SD, n=3, *P=0.0133, ***P<0.0006) P values: Student’s 
t-test, ns=not significant. ((A, C-E) C. Stremmel, (B) R. Böttcher mainly contributed) 
 
5.6 SNX17 regulates integrin-mediated cell functions 
Since kindlin and SNX17 share the same binding site, mutations within this region affect both 
kindlin- and SNX17-mediated cell functions. To overcome this analytical problem, we studied 
cell spreading and migration in SNX17-depleted cells. Reduced spreading and cell motility 
was found in β1 TT/AA and SNX17-depleted cells compared to β1 wt fibroblasts. Moreover, 
in vitro wound healing assays revealed a reduced cell migration velocity in these cells. 
Parallel analyses of β1-null fibroblasts showed almost no migration in these cells (Figure 
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23A-F). In summary, we show that SNX17 exhibits important functional tasks and is a key 
modulator of multiple integrin-mediated processes. 
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Figure 23: SNX17 is required for β1 integrin function 
(A) Quantification of the spreading area of the indicated cell lines (mean±SEM of two 
independent experiments, n=40 cells). (B) Quantification of single-cell migration velocity of 
the indicated cell lines extracted from time-lapse microscopy recordings by single-cell 
tracking (mean±SD of three independent experiments, n=82 cells, ***P < 0.0001). (C) 
Migration analysis of β1 wt, β1 (-/-), β1 TT/AA and SNX17-depleted cells in a scratch assay 
by time-lapse video microscopy. The movement of individual cells into the wound was 
followed using cell-tracking software and representative trajectories are shown (left panels). 
The speed (distance migrated per minute, upper right) and persistence of migration of cells 
(lower right) were quantified from the track plots (means±SD of 52 cells analyzed in six 
individual wounds of two independent experiments, ***P<0.0001). (D) Quantification of the 
spreading area of the indicated cell lines (mean±SEM of two independent experiments, n=40 
cells). (E) Quantification of single-cell migration velocity of the indicated cell lines extracted 
from time-lapse microscopy recordings by single-cell tracking (mean±SD of three 
independent experiments, n=60 cells, *P < 0.0325, ***P < 0.0001). (F) β1 wt, β1 TT/AA, β1 
Y795A and SNX17-depleted β1 wt cells were stained with an antibody against paxillin (red) 
and fluorescently labeled phalloidin to visualize F-actin (green). Nuclei were counterstained 
with DAPI (blue). Scale bar 50 µm. P values: Mann-Whitney U-test, ns=not significant. ((A, 
D, F) C. Stremmel, (B, C, E) R. Böttcher mainly contributed) 
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6 Discussion 
Integrin functions critically depend on receptor affinity regulation for ligands and efficient 
trafficking through endosomal compartments. In this thesis, we identified the new 
cytoplasmic β1 integrin adaptor protein SNX17, which binds integrins in the kindlin-binding 
region in the endosomal compartment and thus prevents lysosomal degradation. For the first 
time, we demonstrated a coupling of affinity regulation by kindlin and of integrin turnover by 
SNX17. 
We showed that both the β1 TT/AA and the β1 Y795A mutation in the kindlin-binding site 
lead to early embryonic lethality – phenotypically similar as described for kindlin-2 knockout 
mice (Montanez et al. 2008). In ES cells, diverse fibroblast cell lines and keratinocytes 
(Stremmel and Fässler, unpublished) with β1 TT/AA or β1 Y795A mutations, we detected 
reduced integrin activity and surface expression despite of elevated mRNA levels. Therefore, 
the kindlin-binding site serves as a determining factor with respect to integrin stability. We 
identified excessive lysosomal integrin degradation as causative for the reduced surface 
expression leading to a secondary reduction in integrin recycling back to the plasma 
membrane. In search of a mechanistic explanation for the reduced β1 TT/AA surface 
expression, we identified a control machinery in which the threonines 788/789 and the distal 
NxxY motif in the cytoplasmic β1 integrin tail regulate integrin affinity at the plasma 
membrane and endosomal integrin trafficking back to the cell surface. Kindlin binds these 
motifs with its F3-FERM-subdomain and the plasma membrane with its PH-domain to 
increase integrin receptor affinity and to establish and modulate links to the actin cytoskeleton 
(Meves et al. 2009; Liu et al. 2011). Upon internalization, kindlin leaves the cytoplasmic 
integrin tail and enables early endosomal SNX17-binding to inhibit lysosomal β1 integrin 
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degradation. This special sequence couples affinity regulation by kindlin with SNX17 as a 
mediator of integrin degradation via the same binding site and is a potential major mechanism 
of integrin quality control. Therefore, integrins with defects in their distal cytoplasmic 
domain, which fail to bind kindlin and SNX17 are subsequently impaired in integrin 
activation and lysosomally degraded. 
SNX17 is a member of the large family of sorting nexin proteins, which are characterized by a 
PX-domain. This domain is specialized on phosphoinositide-binding, especially PtdIns3P, 
which is typically found in endosomal membranes (Cullen 2008). Besides its N-terminal PX-
domain, SNX17 has a C-terminal FERM-domain binding to NxxY motifs as they are found in 
the cytoplasmic integrin tail (Ghai et al. 2011). Due to these unique features, it is not 
surprising that SNX17 has already been described to be involved in transmembrane receptor 
trafficking such as LDLR (Stockinger et al. 2002; Burden et al. 2004), LRP1 (van Kerkhof et 
al. 2005; Donoso et al. 2009), P-selectin (Williams et al. 2004; Knauth et al. 2005) and APP 
(Lee et al. 2008). However, it remains unclear if SNX17 is primarily responsible for recycling 
back to the plasma membrane or inhibits lysosomal degradation. In this thesis, we show that 
lysosomal inhibition rescues the recycling defect of β1 TT/AA integrins, providing clear 
evidence of primary degradation defects, which consequently cause reduced recycling of 
integrins back to the cell surface. How SNX17 regulates degradation on a molecular basis 
remains unclear and needs to be addressed in future studies. One possibility is that SNX17 
prevents that integrins enter inner vesicles of multivesicular bodies – an essential step in 
lysosomal degradation. This could work via the recruitment of a deubiquitinase that removes 
ubiquitin-residues form integrins and thus prevents access of the ESCRT-machinery (Raiborg 
and Stenmark 2009). 
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The early lethality of β1 TT/AA and β1 Y795A mice results from a combination of defects 
including impaired integrin activation, abnormal actin dynamics and reduced integrin 
recycling. Moreover, adhesion, spreading and migration defects of SNX17-depleted 
fibroblasts indicate dramatic abnormalities in integrin function resulting from deregulated 
integrin degradation. Additionally, reduced β1 TT/AA integrin surface expression may also 
affect other cellular processes such as expression and signaling of growth factor receptors or 
co-internalization and resecretion of fibronectin and possibly also other ECM proteins 
(Caswell et al. 2008; Sung et al. 2011). 
One cycle of integrin trafficking, from internalization to recycling back to the cell surface, 
takes almost one hour in our experiments. This seems rather long compared to fast cellular 
processes such as adhesion, spreading and migration which require integrin-dependent 
changes within seconds to minutes. This goes in line with previous studies suggesting integrin 
trafficking as a means of local restructuring (Caswell et al. 2009), which might possibly be 
involved in integrin quality control via SNX17. Going one step further, one could suggest that 
integrins with defects in their kindlin-binding site are not only prone to SNX17-mediated 
degradation but they also liberate kindlin molecules. These could translocate to the nuclear 
region to bind promoter regions and unregulated β1 mRNA levels in order to replace 
degraded integrin heterodimers. We demonstrated for the first time that kindlin is in principle 
capable of increasing mRNA levels. Additionally, previous studies identified a nuclear 
localization signal (NLS) in the kindlin-2 protein and kindlin-2 was shown to be present in the 
nucleus in immunofluorescence experiments (Meves et al. 2009). 
In this study, we provide fundamental insight into integrin trafficking and especially integrin 
degradation. This knowledge is not only of interest for basic research but has also got a broad 
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medical impact, since integrin-mediated physiological and pathological processes play a 
central role in every cell. Especially cancer, infections, thrombosis and autoimmune disorders 
are tightly associated with integrin functions. So far pharmacological inhibitors have been 
approved for three integrins. Recent advances in our understanding of integrins and 
downstream signaling events have created a vast potential for new therapeutic strategies. 
For example, cancer is linked to integrin functions in multiple ways. Integrins mediate cell 
growth by ECM interactions with continuous bidirectional signaling events, which modulate 
proliferation and differentiation. This signaling cascade is further affected by integrin-growth 
factor interactions. Detachment of cancer cells, migration through the tissue, blood vessel 
invasion and metastases formation do all critically depend on integrins. Therefore, it is 
obvious that a fundamental knowledge about integrins is absolutely essential in cancer 
treatment and the development of new therapeutic strategies. 
At the same time, this publication, along with many others, illustrates that integrins are 
essential for every cell and that they are integrated into a highly complex network. Changes in 
this system have severe, partially unpredictable, consequences, which make integrin-related 
therapeutic interventions very challenging. Moreover, the redundancy among integrins, low 
dose agonist-like activity of integrin inhibitors (Cox et al. 2000; Reynolds et al. 2009; Weis et 
al. 2009), as well as the importance of integrins in key physiological systems, make 
therapeutic interventions rather difficult. It will be challenging to unravel how individual 
heterodimers signal their diverse functions and how the same integrin can exert environment-
specific tasks. This knowledge will allow us to establish integrin-targeted therapeutic 
strategies to modulate processes in which integrins have been heavily implicated such as 
cancer formation, inflammation and thrombosis (Lowell and Mayadas 2012). 
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7 Summary 
Integrins are ubiquitously expressed adhesion receptors with important functions in cellular 
adhesion, proliferation, migration and signaling. These functions are determined by integrin 
trafficking through endosomal compartments and receptor affinity regulation. In this thesis, 
we identified the distal NxxY motif of the β1 integrin cytoplasmic tail as a molecular switch 
modulating a spatiotemporally controlled binding of two FERM-domain proteins in different 
cellular compartments. Kindlins mediate integrin activation at the plasma membrane and they 
dislodge upon internalization. In the endosomal compartment, the free cytoplasmic domain is 
subsequently bound by sorting nexin 17 (SNX17) to inhibit integrin degradation. We 
identified SNX17 as a new β1 integrin adaptor protein, which uses the kindlin-binding site in 
endosomal compartments to stabilize integrins and to promote their recycling back to the 
plasma membrane. 
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8 Zusammenfassung 
Integrine sind ubiquitär exprimierte Adhäsionsmoleküle mit entscheidender Bedeutung für die 
zelluläre Adhäsion, Wachstum, Migration und Signalgebung. Diese Funktionen werden durch 
konstantes Integrintrafficking durch endosomale Kompartimente sowie durch Modulation der 
Rezeptoraffinität kontrolliert. Im Rahmen der vorliegenden Dissertation wurde das distale 
NxxY-Motiv im zytoplasmatischen β1 Integrinschwanz als molekularer Schalter identifiziert, 
der die Bindung zweier FERM-Domänen-Proteine in unterschiedlichen zellulären 
Kompartimenten vermittelt. Während Kindline an der Zellmembran die Integrinaktivität 
regulieren, dislozieren sie nach der Internalisierung und Sorting Nexin 17 (SNX17) wird an 
den nun freien β1 Integrinschwanz rekrutiert, um die Integrindegradation zu hemmen. Wir 
haben SNX17 als neuen β1 Integrin-Bindungspartner identifiziert, der die Kindlin-
Bindungsstelle im endosomalen Kompartiment verwendet, um Integrine zu stabilisieren und 
ihr Recycling zurück an die Zelloberfläche zu fördern.  
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9 Graphical summary 
 
Graphical summary 
Kindlin binds the β1 integrin subunit with its FERM-domain to regulate integrin receptor 
affinity. Upon integrin internalization it dislodges and SNX17 is recruited to the free 
cytoplasmic tail. This endosomal binding prevents lysosomal integrin degradation and 
promotes integrin recycling back to the plasma membrane. Specific lipid membrane 
compositions promote the spatial regulation of FERM-domain protein recruitment via 
additional motifs. The kindlin PH-domain is recruited to the PIP2/PIP3 enriched plasma 
membrane (red), whereas the SNX17 PX-domain preferably binds PtdIns3P in endosomal 
membranes (blue). 
 
Grafische Zusammenfassung 
Kindlin bindet die β1 Integrin-Untereinheit an der Plasmamembran und reguliert so die 
Rezeptoraffinität. Nach der Internalisierung verlässt Kindlin den zytoplasmatischen 
Integrinschwanz und SNX17 wird rekrutiert. Diese endosomale Bindung verhindert den 
lysosomalen Integrinabbau und fördert das Integrin-Recycling zurück an die Plasmamembran. 
Spezifische Zusammensetzungen der Lipidmembranen fördern die lokale Bindungsregulation 
der FERM-Domänen-Proteine über zusätzliche Motive. Die Kindlin PH-Domäne wird 
vorzugsweise an die PIP2/PIP3-haltige Plasmamembran (rot) rekrutiert, während die SNX17 
PX-Domäne vorzugsweise PtdIns3P in endosomalen Membranen (blau) bindet. 
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11 Publications 
Abstracts were adapted from the orginal publications. 
11.1 Publication 1: Meves et al. 2009 (Meves et al. 2009) 
Kindlins are a group of proteins that have recently attracted attention for their ability to bind and 
activate integrins. Moreover, they have also been linked to inherited and acquired human diseases 
including Kindler syndrome, leukocyte adhesion deficiency, and cancer. Although most studies have 
focused on kindlins as key regulatory components of cell-extracellular matrix junctions such as focal 
adhesions, preliminary data suggest the involvement of additional cellular compartments in mediating 
their functions, particularly at cell-cell contacts and the nucleus. Investigating the many roles of 
kindlins is likely to expand and sharpen our view on the versatility of integrin-mediated cell adhesion, 
the nuclear function of focal adhesion proteins, and the crosstalk between cell-cell and cell-matrix 
adhesions in health and disease. 
11.2 Publication 2: Böttcher et al. 2012 (Bottcher et al. 2012) 
Integrin functions are controlled by regulating their affinity for ligand, and by the efficient recycling of 
intact integrins through endosomes. Here we demonstrate that the kindlin-binding site in the β1 
integrin cytoplasmic domain serves as a molecular switch enabling the sequential binding of two 
FERM-domain-containing proteins in different cellular compartments. When β1 integrins are at the 
plasma membrane, kindlins control ligand-binding affinity. However, when they are internalized, 
kindlins dissociate from integrins and sorting nexin 17 (SNX17) is recruited to free β1 integrin tails in 
early endosomes to prevent β1 integrin degradation, leading to their recycling back to the cell surface. 
Our results identify SNX17 as a β1 integrin tail-binding protein that interacts with the free kindlin-
binding site in endosomes to stabilize β1 integrins, resulting in their recycling to the cell surface where 
they can be reused. 
